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Aberrant epigenetic alterations, such as DNA methylation, histone modification and 
miRNA-mediated processes, are associated with several types of cancer including 
hepatocellular carcinoma (HCC). HCC is the third leading cause of cancer-related 
fatalities worldwide. Despite the improvements in surgical and medical treatment HCC 
associated deaths are still showing an increase. Methylation defects at the chromosome 
19 miRNA cluster (C19MC) have been shown to be a molecular alteration specific to liver 
cancers and is an attractive candidate for novel HCC therapies. Several C19MC miRNAs 
have been reported to be over-expressed in HCC and C19MC hypomethylation may 
account for this cancer-associated expression. This present study assesses the 
oncogenic effects of C19MC cluster in HCC using epigenetic manipulations. Using 
pharmaceutical and novel targeted epigenome editing tools demethylation was induced 
in HCC cell lines showing a normal hypermethylated state. Demethylation was shown to 
be sufficient to re-activate C19MC miRNAs throughout the cluster. Following 
overexpressing miR-512-3p through miRNA mimics, we showed that upregulation of miR-
512-3p significantly promotes cell invasion. Since abnormal miRNA expression has been 
associated with metastatic spread of tumors, studying changes in miRNA expression 
could help to improve diagnosis and prognosis and provide molecular targets for new 
therapeutic strategies against HCC. Our study suggested that miR-512-3p can be a 
robust marker for HCC prognosis and diagnosis.  
 
2. Introduction. 
2.1. Cancer and basic classifications. 
Cancer is clinically defined as a vast number of complex diseases which have distinct 
behaviours. The behaviours depend on the cell types which they originate from and the 
genetic modifications that occur within each cancer type. The two main properties 
observed in all cancer cells are abnormal cell growth and division and their ability to 
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spread and colonize other parts of the body, known as metastasis. Cancer cells become 
dangerous when cells divide uncontrollably in combination with uncontrolled metastatic 
spread (Klug et al., 2016). Therefore, cancer is the most common cause of 
human fatalities worldwide and its incidence and mortality have shown a rapid increase 
in recent years (Kelly et al., 2017).  
 
There are two main cancer types: benign and malignant. Benign tumor results from loss 
of genetic control over cell growth and is a noncancerous growth (King., 2019). Benign 
tumors neither invade neighbouring tissues nor metastasize to other parts of the body. 
On the other hand, malignant tumors are capable of entering the blood stream or 
lymphatic system, invading other tissues and metastasize. Therefore, malignant tumours 
can become life threatening whereas benign tumors are more common and mostly 
harmless (Klug et al., 2016; King, 2019). Although malignant tumors can spread and 
invade other tissues, all cancer cells in the primary and secondary tumors are clonal. In 
other words, these cells originate from common ancestral cells that accumulate certain 
mutations that cause cancer (Klug et al., 2016). For instance, breast-derived bone 
metastases are tumors formed from cancer cells released from the breast and growing in 
bone tissue. Therefore, these bone metastases are not bone cancer but could be 
considered as ectopic cancerous breast cells that have started growing inside the bone. 
Treatment of these secondary cancers within the bone are difficult, however with the 
correct treatment the size of metastases can be reduced, slow their growth, lessen 
the symptoms, and increase the patients’ life span (Case-Lo, 2016).  
 
2.2. Common molecular mechanisms to Oncogenesis.  
The major changes that characterize cancer are represented by altered oncogenes and 
tumor-suppressor genes (Botezatu et al., 2016). Oncogenes are mutant genes derived 
from proto-oncogenes and are potential carcinogenetic factors (Bagci and Kurtgoz, 
2015; Klug et al., 2016; Nelson,2019). Somatic genetic alterations including gene 
mutations, arrangements, and amplifications (Croce, 2008) result in oncogene activation. 
Mutations causing activation of one allele of an oncogene can interfere with normal cell 
growth and differentiation (Roland, 2009; Klug et al., 2016), leading to cancer initiation 
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and progression (Bagci and Kurtgoz, 2015; Nelson, 2019). On the other hand, tumor-
suppressor genes (TSGs) normally function to suppress cell division (Klug et al., 2016). 
Thus, loss of function of tumor-suppressor genes due to mutations or deletions result in 
activation of cell division and tumor formation (Mendelsohn et al., 2014).       
 
Since cancer is a heterogenous disease, uncontrolled growth of malignant cells occurs 
due to combined genome aberrations, methylation changes, as well as altered miRNA 
expression (Capper et al., 2018; Martincorena et al., 2017). Studies have been focused 
on the origin of tumor cells for over 50 years. Previously it was suggested that mutations, 
amplifications, deletions, and rearrangements were responsible from tumorigenesis 
(Vogelstein and Kinzler, 2004). Our understanding of cancer as a genetic disease has 
evolved since cancer cells gain their characteristics at distinct times in different 
microenvironments during cancer progression, via wide range of mechanisms 
(Hanahan et al. ,2011; Vogelstein et al., 2013).  Genome instability is defined as 
enhanced tendency of the genome to acquire mutations. Genome instability and 
increased mutation frequency can result from defects in DNA repair, DNA replication, 
chromosome segregation or cell cycle control. For instance, defects in DNA mismatch 
repair (MMR), primarily alterations of the MLH1, MSH2 and PMS2 genes result in 
deletions or random insertion and expansion of repetitive DNA sequences 
(microsatellites) and are a characteristic feature of several cancers, including ovarian, 
lung and colorectal cancer (Kim et al., 2000; Pikor et al., 2013). Thus, genome instability 
and faulty repair mechanisms cause mutation accumulation which increases over time, 
playing a role in carcinogenesis (Deman et al,. 2001; Langie et al., 2015). Moreover, 
alterations in the epigenome may indirectly cause genome instability. For 
example, epigenetic modifications can influence DNA repair efficiency and fidelity through 
altering the expression of DNA repair genes (Langie et al., 2013; Langie et al., 2014) or 
genome architecture through widespread hypomethylation.  As will be discussed later, 
epigenetic changes in DNA was shown to be associated with cancer progression and 
DNA methylation was the first epigenetic event studied in tumor cells (Ehrlich, 2009; Shen 






2.3 Hepatocellular carcinoma; causes and sub-types.  
Hepatocellular carcinoma (HCC) is one of the most common tumors and is the third cause 
of cancer-related deaths across the globe. Early stage HCC patients are initially treated 
with surgical resection in combination with adjuvant therapy to improve survival (Bruix et 
al., 2016). However, frequent tumor recurrence has a negative impact on HCC 
patients’ prognosis (Augello et al., 2018).  Most of HCCs are related to hepatitis C virus 
(HCV) or hepatitis B virus (HCB) infections, yet dysplastic liver nodules are often linked 
with different molecular aberrations and gene expression signatures (Augello et al., 
2012). Although genetic mutations and copy-number alterations are well described in 
HCC, Deng et al. (2009 and 2010) characterized infection mediated liver carcinogenesis 
and demonstrated that abnormal promoter methylation may also play an important role. 
Furthermore, several studies have established that epigenetic alterations are one of the 
hallmarks of tumorigenesis (Jones and Baylin, 2002; Shen and Laird, 2013).  
  
2.4 Epigenetic regulation in health and disease. 
Epigenetics is the complex mechanisms that control gene expression by DNA or 
chromatin modifications, without altering the underlying DNA sequence (Pujadas and 
Feinberg, 2012; Klug et al., 2016). Epigenetic processes involve DNA methylation, 
histone modifications and small RNAs. These processes are known to regulate cellular 
mechanisms independent of each other. However, joint activities of different epigenetic 
events were shown to have common consequences, indicating cross talk and 
interdependence between these epigenetic processes (Murr, 2010).  
 
Much of our understanding of gene expression has been obtained through determination 
of gene regulatory elements (Matharu and Ahituv, 2015). Gene expression is not only 
controlled by the promoters but also by distal regulatory elements such as repressors 
which inhibit transcription from promoters, enhancers which target gene promoters 
resulting in gene expression, insulators which disrupt enhancer-promoter cross talk when 
present between them and barriers which prevent heterochromatin spreading through 
9 
 
maintaining borders between euchromatin and heterochromatin regions (Lin et al,. 2011). 
Looping factors, gene regulatory elements and non-coding RNAs play a crucial role in 
enhancer-promoter interactions which have been shown to be associated with 
transcriptional regulation. Hence, abnormal enhancer-promoter interactions can result in 
several diseases, including cancer (Matharu and Ahituv, 2015). Moreover, epigenetic 
modifications have impacts on cellular processes such as transcription regulation, gene 
expression and DNA repair, therefore altered epigenetic regulation is a known cause of 
human diseases (Nojima et al., 2016).   
 
As mentioned above, the roles of epigenetic alterations in health and disease are 
becoming increasingly noticeable.  Deregulation of epigenetic processes is one of the 
significant causes of cancer, hereditary and neurogenerative diseases (Langie et al., 
2015; Holtzman and Gersbach, 2018). Epigenetic aberrations can be categorized into 
four main groups (Fig.1). First category is the loss of function mutation of epigenetic 
modifiers (Holtzman and Gersbach, 2018). DNA methylation modifiers involve DNA 
methyltransferases (DNMT enzymes) and DNA demethylation modifiers involve ten-
eleven translocation (TET) methylcytosine dioxygenases. Loss of TET protein function 
results in aberrant DNMT activity and DNA hypermethylation. Accumulation of 
methylation due to loss of TET activity and enhanced DNMT activity has been associated 
with malignant transformation. Furthermore, it is known that all three TET genes are 
mutated and have decreased expression, and the proteins have disrupted activity in 
various cancer types (Rasmussen and Helin, 2016). For example, somatic alterations of 
TET2 were observed in both myeloid and lymphoid malignancies as well as acute 
myelogenous leukaemia (AML) (Scourzic et al., 2015). Therefore, precise regulation of 
DNA methylation patterns, which involves TET enzymes, is essential for normal 
development and provides a vital protection against cellular transformation (Rasmussen 
and Helin, 2016). The second category states that a disease can also stem from a 
mutation in gene regulatory regions which alters downstream gene expression levels. The 
third category is the inheritance or de novo introduction of epigenetic abnormalities. A 
well-known example is hypomethylation of the H19/IGF2 locus which may cause 
transformation, proliferation and hence cancer. The fourth category is stochastic stress 
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that result from various factors including aging, metabolism, and environmental factors 





Figure 1 Epigenome and Disease. (Figure adapted from Holtzman and Gersbach, 2018) 
Several cellular processes including transcription, DNA repair and gene expression are regulated 
by the epigenetic processes. Therefore, aberrant epigenetic modifications result in human 
diseases. The loss of function mutation of epigenetic modifiers can cause Rett syndrome 
(neurological disorder) and Werner syndrome (autosomal recessive disorder). A mutation in gene 
regulatory regions which alters downstream gene expression levels can also result in diseases. 
Epigenetic abnormalities can be inherited, or de novo introduced. An example is hypomethylation 
at the imprinted H19/IGF2 locus which may cause tumor development. Moreover, some other 
factors such as aging, metabolism or environmental factors may impact cellular functions leading 
to epigenetic abnormalities and disease including type 2 diabetes, cancer, etc. 
 
2.5 DNA methylation.  
DNA methylation is the major epigenetic phenomenon involved in the regulation of 
numerous cellular processes such as imprinting, X-chromosome inactivation, chromatin 
organization, genome stability and gene expression. DNA methylation is classically the 
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covalent addition of a methyl group (-CH3) to the 5’ cytosine that precedes guanine in the 
DNA sequence; the CpG nucleotide, forming 5-methylcytosine (5mC) (Sablok and 
Tatarinova., 2013). DNMTs are responsible from catalyzing the transfer of cytosine to 5-
methylcytosine (Fig.2). Three DNMTS have been identified in mammals; DNMT1, 
DNMT3A and DNMT3B. DNMT1 recognizes hemimethylated CpG nucleotides in the 
parent DNA strand during replication and produces symmetrically methylated sites by 
catalyzing the transfer of the methyl group to the cytosine residues in the unmethylated 
daughter strand. This ensures that propagation of DNA methylation with cell division takes 
place accurately (Newell-Price et al. ,2000; Klug et al., 2016; Gowher and Jeltsch, 2019). 
On the other hand, DNMT3A and DNMT3B can methylate previously unmethylated DNA, 
and are known as de novo methylation, responsible for establishing new methylation 
patterns during development (Bestor et al., 1988; Okano et al., 1998; Okano et al., 1999; 
Holtzman and Gersbach, 2018; Gowher and Jeltsch, 2019).  
 
DNA demethylation is the reverse of methylation; the removal of a methyl group from 5’ 
cytosine of the from CpG dinucleotides (Fig 2). The TET enzyme family (Tet1, Tet2, Tet3) 
play crucial roles in demethylation. TET enzymes catalytically convert 5-mC into 5-
hydroxymethylcyotsine (5-hmC) in presence of 2-oxoglutarate and iron (II) reversing the 
DNMT actions (Tahiliani et al., 2009; Wu and Zhang, 2011; Guo et al., 2011; Rasmussen 
and Helin., 2013). In addition, all three TET enzymes have been reported to further oxidize 
5-hmc to 5-formylcytosince(5-fC) and 5-carboxylcytosine (5-caC) (He et al., 2011; Zhang 
et al., 2012). The modified cytosines frequently undergo deamination, glycosylase 
dependent excision or replaced with unmodified cytosines through DNA repair 
mechanisms (Bhutani et al., 2011; Branco et al., 2012). Together, this indicates that TETs 




Figure 2 DNA methylation. In DNA methylation, de novo methyltransferases DNMT3A and 
DNMT3B add a methyl group (CH3) to 5’ cytosine of the CpG dinucleotides, forming 5-
methylcytosine. After methylation is established by de novo methyltransferases, maintenance 
methyltransferases such as DNMT1 and DNMT3 maintain the methylation marks. 
Demethylation is reverse of methylation in which the methyl group is removed actively by TET 
enzymes. 
 
2.6 Interaction between DNA methylation and histone modifications. 
Methylation of CpG nucleotides can have effects on gene expressions (Fig.3). Cytosine 
methylation is one of the main epigenetic mechanisms responsible for gene silencing as 
it is highly correlated with the inhibition of gene transcription. There are two different 
mechanisms by which DNA methylation suppresses gene expression. The first 
mechanism involves inhibition of binding of specific transcription factors through 
methylation of recognition sequences (Comb and Goodman, 1990; Lewondowska and 
Bartoszek, 2011). The second mechanism involves the recruitment of methylcytosine 
binding proteins (MBPs) and corepressors to methylated DNA. This induces a closed 
chromatin conformation within the area of MBP binding, limiting the access to 
transcription factors, leading to gene silencing (Zardo et al., 2005; Klose and Bird, 2006; 





Figure 3 Methylation of CpG islands causes gene silencing. A) When a gene’s promoter is 
unmethylated, the gene can be transcribed. B) Methylation of a promoter through the addition of 
a methyl group to 5’ cytosine of the CpG islands inhibits transcription hence the gene is silenced. 
 
In addition to DNA methylation, other histone modifications such as histone methylation, 
deacetylation and chromatin binding proteins influence local chromatin structure and 
hence regulate transcription (Baylin, 2005). Some of histone post-translational 
modifications can form extended domains of modified histones by spreading along the 
genome independently of the DNA sequence, influencing genome stability and gene 
function (Zhou et al., 2011). For instance, di/trimethylation of histone 3 at lysine 9 
(H3K9me2/3) and lysine 27 (H3K27me2/3) are enriched in heterochromatin and result in 
gene silencing (Talbert and Henikoff, 2006; Grewal and Jia, 2007; Simon and Kingston, 
2009). H3K9me2/3 can spread around specific response elements within the genome 
(Jermann et al., 2014), resulting in repression of genes within the methylated domains 
(Fig.4) (Baur et al., 2001; Akhtar et al., 2013). Therefore, aberrations in histone 
modifications and the enzymes involved can cause cancer (Geutjes et al., 2012; Plass et 
al., 2013, Holtzman and Gersbach, 2018).  
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Figure 4 Epigenome is complex and diverse. (Figure adapted from Holtzman and Gersbach, 
2018) Epigenetic events involve histone tail modifications, DNA methylation, chromatin looping. 
Several interacting elements facilitate the deposition and removal of these epigenetic features. 
Epigenetic marks and gene regulatory elements can affect gene expression. Significant histone 
modifications associate with active or repressed chromatin (green and pink background 
respectively). Histone modifiers catalyse the accumulation and removal of methylation (Me) or 
acetylation (Ac). Moreover, histone modifications may facilitate other processes, for instance 
phosphorylation (P), SUMOylation (Su) and ubiquitination (Ub). 
 
2.7 Common epigenetic signatures associated with cancer 
Aberrant epigenetic regulation is known to facilitate tumor development. For instance, 
differences in DNA methylation patterns is significant between cancer and non-cancer 
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tissues and cancer-specific epigenetic properties have been identified for every cancer 
type (Nojima et al., 2007; Nojima et al., 2009; Nojima et al., 2016). Although, only global 
DNA hypomethylation was initially shown to be related to the carcinogenic process, linked 
to genome instability and reactivation of retroviral sequences, it is now known that 
alterations in DNA methylation in neoplastic cells are characterized by localized 
hypomethylation and hypermethylation of specific genes (Feinberg and Tycko,2004; 
Ehrlich et al., 2016; Ehrlich, 2019). To be more significant, epigenetic modifications in 
oncogenes and TSGs also cause tumor development. Hypomethylation of oncogene 
promoters can activate oncogenes. For example, activating mutations in RAS oncogenes 
are one of the most common processes in numerous cancers including thyroid and 
colorectal cancers and this gene is frequently hypomethylated in cancer (Botezatu et al., 
2016). On the other hand, hypermethylation of the core promoter in CpG islands has been 
shown to lead to the loss of transcription of classical tumor-suppressor genes including 
p16 and MLH1 in several cancers (Esteller, 2008; Wu et al., 2012). Numerous TSGs in 
an extensive range of cancers have been reported to be inactivated due to promoter 
hypermethylation which frequently occurs in the context if the promoter is embedded 
within a CpG island (Onay et al., 2009; Sebova et al., 2011; Carmona et al., 2012). Thus, 
the methylation status of oncogenes and TSGs not only drive cancer but can serve as a 
potential marker for diagnosis and prognosis prediction (Morris et al., 2010; Ricketts et 
al., 2012). 
 
As mentioned above, the two main differences between the DNA methylomes of cancer 
cells and normal cells is that cancer cells exhibit a global reduction in DNA methylation 
and abnormal hypermethylation of some sequences, primarily CpG islands (Enrilch, 
2009). Aberrant hypermethylation inactivates TSGs and hence is often associated with 
cancer progression (Boyes and Bird, 1992; Feinberg and Tycko, 2004; Sebova et al., 
2012; Carmona et al., 2012). However, analysis of cancer methylomes have shown that 
aberrant CpG hypermethylation takes place predominantly at genes that are already 
silent and is hence not associated with transcriptional silencing of TSGs (Sproul and 
Meehan, 2013). In order for abnormal hypermethylation to directly cause cancer via gene 
silencing, the affected genes must be expressed prior to hypermethylation (Antequera et 
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al., 1990; Sproul et al., 2012). Transcriptionally silenced genes were shown to be the 
primary target of cancer-associated aberrant hypermethylation through the analysis of 
cancer methylomes and gene expression data (Sproul et al., 2012). However, a study in 
colon cancer (Hinoue et al., 2012) demonstrated that 93% of the hypermethylated genes 
in tumors had unaltered expression when compared to normal tissue. The results of this 
suggested that the genes were already repressed, often by bivalent chromatin and 
H3K27me3, in the normal tissue (Hinoue et al., 2012).  
 
2.8 Hypermethylation may affect CFCT sites and later enhancer-promoter looping. 
In vertebrates, insulator protein cohesin and CCTC-binding factor (CTCF) facilitate 
enhancer-promoter interactions by enabling chromatin looping (Krivega and Dean, 2012; 
Matharu and Ahituv, 2015). The role of CTCF proteins in establishing enhancer-promoter 
has been recognised in several previous studies. For instance, Murrell et al. (2004) 
examined DNaseI hypersensitive sites (DHS) in the Igf2-H19 locus. These regions have 
different methylation status on maternal and paternal alleles and the methylation of these 
sites were found to impact the binding of CTCF proteins. This was shown to enable allele-
specific looping of DHs to Igf2 promoter, enhancing the loops and thus resulting in stable 
transcription (Murrel et al., 2004).  
 
Genomic alterations removing CTCF-associated boundaries cause abnormalities in 
enhancer-gene interactions and modify gene expression (Lupianez et al., 2015) due to 
CTCF binding being methylation sensitive (Flavahan et al.,2016). Therefore, cancer-
associated hypermethylation is not only involved in gene suppression by promoter 
hypermethylation, but can alter CTCF localization (Hark et al., 2000; Bell and Felsenfeld, 
2004), resulting in loss of insulation between domains causing aberrant gene expression 
(Flavahan et al., 2016). It is crucial to note that altered CTCF loops can cause both 
transcriptional activation and repression, showing the importance of CTFC in genomic 






2.9 Cancer associated hypomethylation. 
Global DNA hypomethylation occurs frequently in neoplastic tissues. Loss of 
maintenance methyltransferases DNMT1 or TET-mediated oxidation of methyl cytosine 
can cause passive and active DNA hypomethylation respectively (Cortellino et al., 2011; 
Smith and Meissner, 2013). Although promoter CpG islands are often hypermethylated 
in tumors, DNA hypomethylation is found in neighbouring CpG island shores and 
repetitive elements (Luo et al., 2014). Hypomethylation of intronic and intergenic regions 
occur early in the transition from normal to neoplastic, indicating the role of DNA 
hypomethylation in genome instability and cancer initiation (Sheaffer et al., 2016). Not 
only DNA hypomethylation but also promoter hypomethylation can lead to cancer. For 
instance, hypomethylation of an intergenic CpG island on chromosome 19 is associated 




MicroRNAs (miRNAs) are small non-coding RNAs derived from 70-100 nucleotide long 
precursors molecules consisting of a double-stranded stem loop as well as single-
stranded regions (Klug et al., 2016; Takahashi et al., 2019). These double-stranded stem 
loop structures are recognized and cleaved by nuclease enzymes in the nucleus during 
RNA-induced gene silencing (RNAi), revealing the involvement of miRNAs in RNAi gene 
silencing (Fig.5) (Klug et al., 2016). It has been shown that the sequence specific binding 
of miRNAs to 3’ untranslated region (UTR) of their target messenger RNA (mRNA) can 
induce transcript degradation or inhibition of protein translation (Takahashi et al., 2019).  
In addition, miRNA can block the translation or facilitate the cleavage of their target mRNA 
via binding to their coding sequences (Hausser et al., 2013; Forman et al., 2014; Ito et 
al., 2017). Hence, miRNAs negatively regulate their target genes, silencing gene 
expression (Takahashi et al., 2019). miRNAs are expressed by many eukaryotic plants 
and animals (Carthew and Sontheimer, 2009). Transcription of miRNAs is carried out by 
RNA polymerase II (Rossi, 2009). Occasionally several miRNAs can be produced from a 
single transcript, whereas other miRNAs are individually produced from distinct 
transcription units (Bartel, 2004). Thus, a transcript can encode either clusters of different 
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miRNAs or a miRNA and a protein-coding mRNA. Studies of the latter type of locus 
reveals that the miRNA sequence is often located within an intron of the mRNA (Lu et al., 
2008; Carthew and Sontheimer, 2009). 
 
The processing of miRNAs can be either from the sense or antisense strand of the gene 
encoding them and takes place in the nucleus and in the cytoplasm (Rossi et al., 2009). 
In the nucleus, miRNA genes are transcribed by RNA polymerase II as primary miRNA 
(pri-miRNA) (Rossi et al., 2009; Takashai et al., 2019). These primary transcripts are 
further processed in the nucleus into precursor miRNA (pre-miRNA) by a protein complex 
that involves a double-stranded RNA (dsRNA) specific ribonuclease Drosha (Banaudha 
and Verma., 2012). These pre-miRNAs are then exported into the cytoplasm by the 
nuclear export protein exportin-5 where they are further cleaved into short, linear double 
stranded miRNAs by the Dicer complex (Klug et al., 2016; Takashai et al., 2019). Either 
the RNA-induced silencing complex (RISC) or the RNA-induced transcription silencing 
complex (RITS) recognizes the short double stranded RNA molecules and degrades one 
of the strands. The RISC complex is guided by the anti-sense single-stranded RNA in the 
RNAi pathway and marks the target mRNA substrates for degradation or inhibiting 
translation. The mature miRNA binds to complementary sequences in the 3’ UTR or 
coding regions of its target mRNA, causing mRNA degradation or transcriptional 
repression (Takashai et al., 2019). On the other hand, in the transcription silencing 
pathway, the RITS complex recognizes the genomic DNA which is complementary to the 
single strand of the miRNAs. The RITS complex recruits enzymes that alter chromatin 
structure and suppress transcription (Fig.5). Having impacts on chromatin-mediated gene 
silencing proposes the involvement of miRNA molecules in epigenetic events including 




Figure 5 Gene regulation by RNA-induced gene silencing mechanism. (Figure adapted from 
Klug et al., 2016). Stem loop structures of miRNAs are cleaved by nuclease within the nucleus 
and are transported to cytoplasm. In the cytoplasm, the Dicer complex processes the miRNA 
precursors into short double stranded RNA molecules. These double stranded RNA molecules 
are recognized by either the RISC or the RITS complex, resulting in the degradation of one strand. 
In RNAi pathway, RISC complex guided by antisense single-strand RNA recognizes target mRNA 
substrates and marks them for degradation or translation inhibition. The RITS complex acts in the 
nucleus in the transcription silencing pathway and is responsible for recruiting enzymes that alter 
chromatin and suppress transcription. Degradation of mRNAs, inhibition of translation and 







2.11 miRNAs and their involvement in cancer. 
miRNAs can function as oncogenes or tumor suppressor genes (Gailhouste et al., 2013; 
Takahashi et al., 2014; Takahashi et al., 2015; Nezu et al., 2016). This is because in 
addition to gene silencing, miRNAs have crucial roles in several biological processes 
including cell proliferation (Hwang and Mendell,2006), development (Karp and Ambros, 
2005), differentiation (Chen et al., 2004; Shivdasani, 2006), metabolism (Wienholds and 
Plasterk,2005), genome instability (Caffarelli et al., 2011) and DNA repair (Chowdhury et 
al., 2013). Therefore, dysfunctional miRNAs cause abnormal cell behaviors and shown 
to be associated with the development and progression of many human diseases, notably 
cancer (Lages et al., 2012; Lan et al., 2015).   
 
Oncogenic miRNAs and oncogenic epigenetic changes have been reported in HCC 
(Shen et al., 2012; Xia et al., 2013). For instance, miR-216a and b were shown to have 
upregulated expression and oncogenic behavior in HCC (Xia et al., 2013). miR-182 was 
shown to keep HIF1α pathway continuously active by targeting PHD2 and FIH1 which 
could facilitate tumor cell adaption to hypoxic stress during prostate tumor progression 
(Giraldez et al., 2018). However, certain miRNAs have oncogenic activities in one 
scenario but can be tumor suppressive in another (Svornos et al., 2016). For example, 
mir-125b functions as an oncogenic miRNA in several hematological malignancies but as 
a tumor suppressor in many solid tumors (Shaham et al., 2012; Sun et al., 2013). The 
location of cancer cells may determine whether a miRNA has a net oncogenic or net 
tumor suppressive effect (Svornos et al., 2016). 
 
Aberrant miRNA methylation has been linked with cancer, underlying their biological 
significance in general tumorigenic processes (Ramasson et al., 2018). Initially, 155 out 
of 332 human miRNAs were found to be regulated by DNA methylation (Weber et al. 
,2007). In another previous study, following stable depletion of DNMT1 and DNMT3B in 
a colorectal cell line, miR-124a, miR-373 and miR-517c were proposed to be 
transcriptionally inhibited by methylation (Lujambo et al., 2007). Moreover, miR-9, miR-
34b/c, and miR-418a were demonstrated to be silenced due to hypermethylation in 
metastatic cell lines from colon, melanoma, head, neck, primary colon, head, breast, lung 
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cancers (Lujambo et al., 2008). In HCC, several miRNAs including miR-1, miR-9, miR-
34b, miR-124, miR-148a and, miR-200b were confirmed to be aberrantly methylated 
(Furtura et al., 2010; Xie et al., 2014; Zhang et al., 2015; He et al., 2015). Therefore, 
miRNAs are regulated by epigenetic modifications including DNA methylation. However, 
miRNAs can regulate epigenetic machinery at the post-transcriptional level through 
establishing epigenetic loops. For example, DNMT1 is aberrantly upregulated in breast 
cancer which results in hypermethylation of miR-148a and miR-152 promoters, forming 
an epigenetic loop (Braconi et al., 2010; Zhang et al., 2011; Xu et al., 2013). 
 
2.12 Cancer-associated hypomethylation and miRNAs. 
miRNA expression can be controlled by DNA methylation although the correlation is not 
always positive or negative and is region dependent (Manodoro et al., 2014). Even though 
DNA methylation modifications in CpG islands within promoters have been extensively 
studied, the dynamical and functional importance of DNA methylation in other regions, for 
instance non CpG island sites, including gene bodies is not fully understood (Yang et al., 
2014; Nojima et al., 2016). Tumors often have reduced levels of mature miRNAs (Lu et 
al., 2005) due to genetic loss, epigenetic silencing, errors in the biogenesis pathway or 
widespread transcriptional repression (Jansson and Lund, 2012). Hence, cancer can 
result from upregulation of potentially oncogenic miRNAs due to cancer-specific miRNA 
cluster hypomethylation (Brueckner et al., 2007; Iorio et al., 2007; Nojima et al., 2016; Lu 
et al., 2018). Recently, Lu et al. (2018) showed upregulation of miR-10b-3p due to 
promoter hypomethylation, which subsequently resulted in the up-regulation of FOXO3 in 
esophageal squamous cell carcinoma. In some cases, hypomethylation and the 




A cluster of miRNAs located on human chromosome 19, known as the chromosome 19 
miRNA cluster (C19MC) is primate-specific and exclusively expressed in the placenta 
(Dumont et al., 2017).  C19MC consists of 46 highly homologous miRNA genes within a 
100 kb genomic region. Since it comprises approximately 8% of all known human miRNA 
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genes, C19MC is regarded as the largest miRNA gene cluster in the human genome 
(Fig.6) (Bortatin-Cavaille et al., 2009; Donker et al., 2012). C19MC cluster of mature 
miRNAs is believed to originate from tandem duplication of one member of the 




Figure 6 Diagram of C19MC cluster. (Diagram adapted from Donker et al., 2012) C19MC cluster 
is 100kb long and consists of 46 miRNAs. These miRNAs are exclusively expressed in placenta 
and regulate gene expression in maternal tissue. 
 
C19MC miRNAs have crucial roles not only in reproduction but also development and 
differentiation in primates (Lin et al., 2010). Being restrictively expressed in reproductive 
tissues and not in other adult tissues shows the developmental importance of C19MC 
(Liang et al., 2007; Razak et al., 2013). Additionally, C19MC miRNAs can regulate gene 
expression in maternal tissue and influence maternal physiology when secreted within 
the exosomes from the trophoblast layer into maternal circulation (Dumont et al., 2017). 
In the human placenta, C19MC is expressed en bloc from the paternal allele which is 
controlled by a major promoter located 17.6 kb upstream of the first miRNA in the cluster 
(Noguer-dance et al., 2010). Bortolin-Cavaille and collaegues (2009) suggested that the 
transcription of the C19MC cluster is controlled by specific methylation dynamics of this 
upstream CpG-rich promoter region to generate a primary transcript containing the entire 
cluster. Hypermethylation of both paternal and maternal alleles (Noguer-dance et al., 
2010), is responsible for the restricted expression profile and silencing in normal somatic 
tissues (Liang et al., 2007; Lin et al., 2010). On the other hand, the maternal allele was 
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found to be unmethylated in the placenta resulting in paternal-allele expression of the pri-
C19MC transcript (Tsai et al., 2009; Noguer-dance et al., 2010). This can subsequently 
be splicing to produce the individual precursor miRNA species which are later processed 
by the DGRC-8 Drosha microprocessor complex to generate the mature miRNAs 
(Bortolin-Cavaille et al., 2009). Uniquely, the C19MC miRNAs are related to each other 
and located within 400-700 bp repeated sequences bounded by Alu repeats (Alus) (Fig.7) 
(Borchert et al., 2006; Nouger-Dance et al., 2010). 
 
 
Figure 7 Schematic diagram of C19MC cluster. (Diagram adapted from Nouger-Dance et al., 
2010). In this diagram, black triangles represent Alu repeats and stem-loop structures represent 
pre-miRNA genes.  Most pre-miRNA genes are localized within repeated introns flanked by Alu 
repeats. 
 
Borchert et al. (2006) suggested that the upstream Alus have Pol-III promoters which 
drive the expression of the downstream C19MC pri-miRNA genes. However, re-
assessment of the organization and expression of C19MC miRNAs suggests it is unlikely 
that Pol-III-dependent transcription occurs and instead the miRNAs are processed from 
the large non-coding placenta specific transcripts generated by Pol-II (Bortolon-Cavaille 
et al., 2009). 
 
2.14 Oncogenic effects of C19MC. 
Results of a recent study (Nyguen et al., 2017), showed that C19MC miRNAs were 
selectively activated in cancer cells, suggesting the functional role in promoting cancer 
development. The re-expression of the miR-515-3p, miR-518a-3p, miR-520f and miR-
525-3p have all been shown to be selectively over-expressed in HCCs (Augello et al., 
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2012). Preliminary data from the Monk laboratory demonstrated that C19MC promoter 
hypomethylation is specific to HCC and occurs in 30-40% of cases and may account for 
this cancer-associated expression. This is supported by the fact that a comparison of 
normal and cirrhotic liver tissue revealed that over-expression of miR-519d occurs only in 
the HCC samples with hypomethylation (Fornari et al., 2012). 
 
Re-expression often impacts almost all C19MC miRNA members resulting in dynamic 
interactions between miRNAs and their target genes. Some C19MC miRNAs are 
associated with oncogenic functions whereas other have tumor-suppressive effects (Flor 
and Bullerdiek, 2012). Interestingly, several C19MC miRNAs are known as context-
dependent miRNAs having both oncogenic and tumor-suppressive properties (Kasinksi 
and Slack, 2011). C19MC miR-519a-3p, miR-519b-3p and miR-519c-3p were classified 
as potential tumor-suppressors as they were found to induce cellular senescence by 
suppressing HuR (Marasa et al., 2010; Abdelmhosen et al., 2010). However, miR-519d 
was shown to directly target CDKN1A, PKTEN, AKT3 and TIMP2, resulting in promotion 
of cell proliferation and invasion, and inhibition of apoptosis (Fornari et al., 2012). 
 
2.15 The significance of miRNAs in cancer diagnosis and prognosis. 
Endogenous circulating miRNAs drew distinctive attention since they have potential 
applications in the diagnosis, prognosis, and metastasis of cancer (Lu et al., 2018).  
Tumor-derived miRNAs were first discussed in plasma by Mitchell et al. (2008) and it has 
been indicated that investigation of plasma miRNAs is highly promising for clinical uses 
(Lu et al., 2018). Although extensive resources are available for studying the influence of 
miRNAs on human diseases, there are undiscovered associations between miRNAs and 
diseases. Thus, it is essential to improve understanding towards the involvement of 
miRNAs in human diseases (Chen et al., 2019).   
 
Despite improvements in tumor diagnosis and therapy, survival rate is approximately 5 
years and still remains low (Wu et al., 2018). Hence, it is vital to explore underlying 
molecular mechanisms in order to facilitate the early diagnosis and therapy for cancer. 
The biological functions and expression of C19MC members in cancer cells have not 
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been investigated in a cluster-wide manner (Nguyen et al., 2017). Since pathogenesis, 
growth and metastatic spread of tumors have been associated with abnormal miRNAs 
expression, miRNAs have been suggested to be novel potential, diagnostic or predictive 
biomarkers in HCC (Augello et al., 2012; Lin et al., 2012; Vaira et al., 2015). Therefore, 
studying changes in miRNA expression could help not only to improve diagnosis and 
prognosis but also provide molecular targets for new therapeutic strategies against HCC 
(Augello et al., 2018). 
 
2.16 Introducing epigenetic manipulation. 
Less than 3% of the human genome is made up of gene coding regions (Encode proj. 
Consort, 2012) and intergenic or intronic regions consist of approximately 90% of the 
single-nucleotide polymorphisms (SNPs) which are associated with human diseases 
(Hindorff et al., 2009). Targeted deletions and mutations in intergenic regions, for instance 
enhancer, have significant impacts on gene expression, suggesting that there is a 
regulatory network between coding and non-coding regions of the genome (Korkmaz et 
al., 2016). 
 
Epigenetic components including DNA methylation, histone modifications, chromatin 
accessibility and DNA architecture are significantly associated with cellular processes, 
hence their dysregulation alters gene expression and cause disease (Ernst et al., 2011 
;Rao et al., 2014;.Kundaje et al., 2015; Merkenschlager and Nora, 2016; Yin et al., 2017). 
Selective modification of epigenome not only improves our understanding of the function 
of epigenetic modifications but also allows manipulation of cell phenotype for research or 
therapeutic purposes (Holtzman and Gersbach, 2018). The improvements in genome-
editing tools that can target specific DNA sequences with increased precision and 
efficiency has led to development of targeting platforms comprising mainly zinc fingers 
(ZFs), transcription activator-like effectors (TALENs) and the CRISPR/dCas9 system (Gaj 
et al., 2013). These platforms are different from each other in terms of ease of use, 
implantation, and flexibility (Thakore et al., 2016). The Monk laboratory has an interest in 
epigenome editing tools encompassing the CRISPR/dCas9 system since it is relatively 




2.17 Epigenetic manipulations by non-specific small molecules. 
Genetic manipulation techniques involve use of non-targeting small molecule inhibitors. 
Small molecule libraries are collections of chemical compounds which have biological 
activity. Small molecule libraries have been extensively used in various high-throughput 
screens with the aim of identifying targets associated with certain effects. The use of small 
molecules, primarily in the pharmaceutical industry, has led to the discovery of wide range 
of drugs including mevastatin and cyclosporin A. Some of these drugs target enzymes 
which deposit epigenetic marks and are predominantly used for research and anticancer 
treatment purposes. DNMT1 and DNMT3 inhibitors azacitidine (5-azacitidine, 5-aza) and 
decitabine (5-aza-deoxyctidine, 5-aza-DC) as well as histone deacetylase (HDAC) 
inhibitors suberoylanilide hydroxamic acid (SAHA) and romidepsin (depsipeptide ir 
FK228) are some of the commonly used small molecules in the clinic (Holtzman and 
Gersbach, 2018). Since these compounds lack specificity, they may cause unknown 
effects at other loci and tissues. Additionally, lack of specificity limits the dose range which 
they can be effectively used, limiting the potency of inhibition (Holtzman and Gersbach, 
2018). 
 
2.18 Locus-specific examples, ZNF- fusions. 
To overcome the non-specific nature of small molecular remodelling of DNA methylation, 
DNA-binding zinc finger proteins (ZNF) were utilized in targeted editing, initiating a new 
era not only in genomic but also in epigenomic manipulation (Urnov et al., 2011; Adli, 
2018). These DNA binding proteins consisting of protein motifs or fingers recognize and 
bind to three DNA nucleotides (Urbano et al., 2019). DNA-binding domains (DBD) are 
engineered in ZNFs, hence they can recognize specific target nucleotide sequences 
(Urnov et al., 2011). Combination of different ZNF modules are used based on their 
respective affinities for a specific three base sequence so that specific genomic regions 
can be targeted (Urbano et al., 2019). Therefore, DBDs of ZNFs are mainly fused with a 
nuclease or other effector protein to mediate a site-specific genetic or epigenetic 
response (Urnov et al., 2011; Grimmer et al., 2014; Chatterjee and Eccles, 2015; Adli, 
2018). However, since each ZNF-fusion requires a unique set of ZNF modules to 
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recognise DNA, each region to be targeted needs separate ZNF-fusion which requires a 
huge cloning effort. 
  
2.19 Epigenetic manipulations, TALEN-fusions. 
Transcription activator-like effectors (TALENs) are also DNA-binding proteins whose 
DBDs are designed to target specific nucleotide sequences (Christian et al., 2012).  
TALEs were isolated from the Xanthomonas bacteria and were next developed for 
targeted editing (Adli, 2018).  TALEs are dimeric transcription factors or nucleases made 
from arrays of amino acid modules. Like ZFNs, fusion of Fok I DNA cleavage domain to 
a combination of TALE modules produce an effective nuclease called TALENs (Li et al,. 
2011). Like ZNF proteins, TALES enable sequence-specific DNA binding, yet TALES can 
bind individual bases at a target locus. Also similar to ZNFs, TALES can induce a certain 
effector response at a targeted locus when fused with specific effector proteins (Joung et 
al., 2013; Adli, 2018), but suffer from the same disadvantages. 
 
2.20 Epigenetic manipulations, dCas9-fusions. 
Although ZNF and TALE-based technologies enable genomic and epigenomic editing at 
a single locus, these techniques are difficult and laborious as each targeting site requires 
a full re-design and re-engineering of a new set of proteins. On the other hand, CRISPR-
based technologies have simpler and easily targetable systems and provide a better level 
of editing efficacy (Urbano et al., 2019).  
 
The first CRISPRs were detected 33 years ago during the analysis of the gene 
responsible for isozyme conversion of alkaline phosphates in Escherichia coli (E. coli) 
(Ishino et al., 1987). The CRISPR/Cas9 system was first explored as an adaptive immune 
response mechanism of bacteria against invading viruses (Mojica et al., 2005). The 
CRISPR loci consists of a clustered set of Cas (CRISPR associated) genes surrounded 
by identical repeat nucleotide sequences with spacer in between (Jansen et al., 2002). 
The nucleotide spacers were obtained by Cas enzymes from exogenous protospacers 
following the invasion of viruses. If the same virus invades, the Cas9 cleaves the same 
specific genetic element as the spacers recognize and target the same foreign agent. 
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Consequently, double-stranded cleavage is induced in the foreign DNA as an adaptive 
immune response (Doudna et al., 2014). 
 
The CRISPR- based tool modulating DNA methylation at a target locus is represented by 
the fusion of the effector protein component to the CRISPR-deactivated Cas9 (dCas9) 
targeting protein (Adli, 2018). For instance, DNMT3A enzyme has been fused to dCas9 
for targeted methylation editing (Fig.8A). Moreover, the fusion of TET dioxygenase 
enzyme with dCas9 allows selective demethylation of the epigenome (Fig.8B) (Urbano et 
al., 2019).  Apart from selective methylation and demethylation, CRISPR-dCas9 system 
is also used to manipulate distal regulatory elements. Hilton et al. (2015) showed that 
CRISPR-dCas9 based acetyltransferase results in the activation of genes from promoter 
and enhancers manipulations, suggesting dCas9-fusions have a diverse range of 
potential uses (Hilton et al., 2015). 
 
  
            
 
Figure 8 CRISPR/Cas9 for selective methylation and demethylation. (Figure adapted from 
Urbano et al., 2019) The light orange image represents the CRISPR-dCas9 protein complex 
which is required along with a unique guide RNA sequence fused to the single-guide RNA plasmid 
construct for targeted editing. A) For locus-specific methylation, the epieffector DNMT3A (green) 
catalyzes the addition of methyl groups. B) For locus-specific demethylation, the epieffector used 
is Tet1 (red) enzyme which removes the methyl marks (Urbano et al., 2019). 
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2.21 The principles of dCas9 epigenetic targeting. 
The best characterized system for genome and epigenome manipulations, as described 
above is the type II CRISPR system used by Streptococcus pyogenes. This system 
involves the Cas9 nuclease, a CRISPR RNA (crRNA) and trans-activating CRISPR RNA 
(tracrRNA). The crRNA hybridizes with the tracrRNA recruiting Cas9 and binds to foreign 
protospacer elements (Ran et al., 2013).  The two RNAs can be joined forming a chimeric, 
single-guide RNA (sgRNA) (Jinek et al., 2012). Modification of this guide RNA (gRNA) 
molecule through alteration of the 20 bp guide sequence in the spacer can direct Cas9 to 
almost any target (Urbano et al., 2019). In the CRISPR-Cas9 system derived from 
S.pyogenes, the target sequence is required to immediately follow a 5’-NGG protospacer-
adjacent motif (PAM). PAM recognition is essential for ATP-independent strand 
separation. In addition, PAM recognition is required for gRNA complexing with target 
genetic elements (Jinek et al., 2012). 
 
For epigenome manipulation, the underlying DNA sequence does not need to be cleaved. 
Thus, the Cas9 nuclease is deactivated for removal of the catalytic activity. Single-amino 
acid substitutions of Asp10 to Ala10 and His840 to Ala840 create nuclease-deficient 
dCas9 (Doudna, 2014). Ongoing researches aim to optimize and improve the use of 
CRISPR-deactivated Cas9 (dCas9) for targeted editing (Urbano et al., 2019).  The 
fundamental requirement for CRISPR dCas9 fusion for epigenome editing comprises of 
three vital parts: a DNA-binding targeting protein, an effector protein, and a unique gRNA 
sequence (Fig 9). The CRISPR-dCas9 system is an optimal targeting protein complex 
since it can be targeted by gRNAs to multiple sites and is insensitive to CpG methylation 
(Perez-Pinera et al., 2013; Hilton et al., 2015).  I took the advantage of the fact the Monk 
laboratory has cloned several dCas9-fusion constructs, including dCas9-DNMT3-CD and 
dCas9-TET-CD that contain the minimal catalytic domains of methyltransferase and 




 Figure 9 CRISPR/dCas9 components. (Figure adapted from Urbano et al., 2019) The CRISPR-
dcas9 protein complex, a unique gRNA sequence fused to the sgRNA and the effector domain 
are required for selective methylation or demethylation. dCas9 serves as a DNA binding domain 
(Enriquez,2016). The effector domains are DNMT3A or TET for methylation and demethylation, 
respectively. dCas9 protein can be fused to repetitive peptide epitopes (SunTag) to recruit 
multiple copies of antibody-fused effector domains (Huang et al.,2017).  
 
3. The aim of this project. 
The goal of this study was to examine the oncogenic effects of the C19MC cluster in 
hepatocellular carcinomas through epigenetic manipulation. Taking the advantage from 
previous studies in the Monk laboratory, I investigated the links between aberrant DNA 
hypomethylation in HCC cell lines that drive the re-expression of oncogenic miRNAs. I 
focused my experiments in HCC that have retained hypermethylation of the C19MC 
promoter, including HepG2 and HLF. Specifically, I tried to: 
(1) Profile C19MC methylation and determine miRNA expression in HCC cell lines. 
(2) Re-express C19MC associated miRNAs using small molecular inhibitiors 5-aza-
deoyctidine (5-aza-DC) and Trichostatin A (TSA) which results in global demethylation 
and histone acetylation, respectively (Mossman et al., 2010). 
(3) Generate stably expressing HLF cell containing the dCas9-Tet1 construct to 
demethylate the C19MC promoter in a targeted fashion through the use of multiple 
gRNAs. 
(4) Determine the effect of specific C19MC miRNA re-expression using miRNA mimic. 
(5) For the cells generated in aims 3 and 4, assessed cellular behavior, migratory potential 




4. Materials and Methods. 
4.1 Cell Culture Protocols. 
4.1.1. Growing cell lines. 
Human hepatocellular carcinoma cell line HLF was purchased from American Type 
Culture Collection and HepG2 was a gift from Prof Manel Esteller, IDIBELL, Barcelona. 
The cells were cultured in Dulbecca’s Modified Eagle’s Medium (DMEM) containing 10% 
Fetal Bovine Serum (FBS) and 1% penicillin- streptomycin (P/S) at 37°C and 5% CO2. 
Cryopreserved cells were rapidly defrosted to room temperature, resuspended in 5ml of 
growth media and centrifuged at x1100g for 5 min. Following centrifugation, the media 
was removed, and the cell pellets were resuspended in an appropriate volume of growth 
medium and dispensed into sterile flasks. During passaging of cells, 3 ml per 25 cm2 of 
trypsin-EDTA was added to the culture flasks once the culture media had been removed 
and the flasks were incubated for 5 min. Once the cells were detached, 3 ml of DMEM 
media containing FBS was added to inhibit the reaction and recentrifuged to collect the 
cells (x1100g for 3 min). The media was subsequently aspired, the cell pellets 
resuspended in appropriate volume of growth medium and seeded in sterile flasks. 
 
4.1.2. 5-aza-DC treatment, optimization of concentration and duration. 
To facilitate global demethylation, HLF cells were incubated with 5-aza-DC (Sigma-
Aldrich). The stock solutions were stored at –80°C and the various working concentrations 
of 5-aza-DC were prepared fresh daily by diluting in PBS. To determine the optimal 
concentration for my experiments, I performed MTT to identify the IC50 and cell counts. 
Five different concentrations of 5-aza-DC were compared to a control (0 µM); 0.5 µM, 1 
µM, 2.5 µM, 5 µM and 10 µM for either 24h, 48h, 72h and 96h. HLF cells were seeded in 
6-well plates and when at ~40% confluency the 5-aza-DC treatments began. Cell counts 
were performed using 10 µl of trypsinized cells, the remainder stored at -80°C for 
subsequent DNA extraction. 
 
MTT assay was carried out to assess cell viability. HLF cells were seeded in 96-well plates 
with each well containing 10,000 cells in 100 µl of media. Thiazolyl blue tetrazolium 
bromide (Sigma-Aldrich) of 0.1 g was dissolved in 20 ml of PBS 24h before the MTT 
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assay. The media in 96-well plate was removed and 100 µl of DMEM media and 100 µl 
MT2 solution was added to each well. After 3h of incubation, the media was once again 
removed and 250 µl of DMSO was added. The plate was put on a rocker for 30 min to 
allow the crystal to dissolve. A plate reader was used to determine the absorbance at 
wavelength of 560 nm as the amount of absorbance is proportional to the cell number. 
 
4.1.3 Combined 5-aza-DC and TSA experiment. 
When the laboratories reopened following the COVID-19 lockdown, I regrew and 
stabilized my HLF cells. The cells were then treated with 5-aza-DC alone, in combination 
with TSA and TSA alone (Sigma, Aldrich) to induce global demethylation and histone 
deacetylation, respectively. HLF cells were seeded when at 60% confluency and 24h prior 
to the treatment. The cells were added with 10 µM of 5-aza-DC and incubated for 3 days, 
7 days and 10 days. Previous studies showed that 100-400 nM TSA in combination with 
5-aza-DC (for the last 24h of the culture) results in high expression (Mossman et al., 2010; 
Zych et al., 2013). Hence, we added 100 nM of TSA at the last 24h before harvesting 
cells for DNA and RNA extraction. The culture media was replaced every 24h with fresh 
media containing 5-aza-DC. 
 
4.1.4. Transfections with Lipofectamine, PEI and JetPrime. 
Initially, common transfection reagent Lipofectamine (Invitrogen) (10 µl for 5 µg of DNA 
in 250 µl DMEM) was used to deliver the dCas9-TET-CD construct into HCC cell lines. 
Green fluorescent protein (GFP) was used as a marker for detecting transgenic 
expression as our initial construct contained T2A-GFP. Transfection controls included the 
pMax-GFP plasmid.  The transfected cells were incubated for 48h and analysed under a 
fluorescent microscope. In addition, dCas9-TET-CD fusion was delivered into the cells 
with Polyethylenimine (PEI) solution (120 µl PEI solution for 10 µg dCas9 plasmid in 500 
µl DMEM). In addition to the dCas9-TET-CD-T2A-GFP plasmids, we also used a 
construct in which GFP had been replaced with the puromycin-N-acetyltransferase gene. 
Following 72h of incubation with this second plasmid, the transfected cells were seeded 
into new plates and exposed to media containing puromycin (ThermoFisher Scientific) 
(DMEM+ 10% FBS + 1% FBS + 400 µl puromycin) and cells were analyzed 72h later. 
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Lastly, JetPrime (Polyplus transfection agent) was used for dCas9-TET-CD delivery (200 
µl JetPrime buffer and 4 µl of JetPrime reagent for 2 µg of DNA) to try and find the best 
delivery agent for these large constructs. 
 
4.1.5 Infections of dCas9-TET lentivirus. 
Lentiviral transfer of pLV hUbC-dCas9-TET-T2A-GFP and Fuw-dCas9-TET-CD 
(Addgene 84475-LVC, 1.8x10^8 TU/ml), containing 5’LTR sequences flanking the 
transgenes, into the HCC cell lines was utilized. HLF cells were seeded into 6-well plate 
in 2 ml media 24h prior to lentiviral infection. Lentivirus of 15 µl was added to 100 mg/ml 
polybrene containing culture media and each well was added with 500 µl 
Lentivirus/Polybrene mixture. The virus treated HLF cells were cultured for 48h and were 
seeded into a 6-well dish and 10 cm plates. The cells in 6-well dish were then infected 
with Fuw-dCas9-TET-CD lentivirus for the second time. Media was replaced with 
complete DMEM 48h after infections. The cells were grown for 2 weeks to prevent 
transiently expressing cells masking the stable cell lines. Colonies were split so that 
cultures would be maintained while DNA was extracted for dCas9 PCR.  
 
4.1.6 miRNA mimics. 
For miRNA over-expression experiments we used chemically synthesized miRCURY 
LNA miRNA mimic (Qiagen)(Fig.10). The miR-512-3p mimic of 5 nmol was initially 
resuspended in 75 µl of H2O to yield a concentration of 66.67 µM. Stock solutions of 50 
nM were stored at -20°C. JetOptimus DNA transfection reagent (Polyplus transfection) 
was used to transfer the mimic into HLF cells.  The cells were seeded into 6-well plates 
24h prior the transfection. To each well we added with 200 µl of JetOptimus buffer, 3 µl 
of JetOptimus transfecting reagent and 1.5 µl of the mimic. We used Cel-mir-39 control 
mimic in addition to control HLF cells that were exposed to JetOptimus with cargo DNA. 




Figure 10 miRCURY LNA miRNA mimic. Generally, the mature miRNA mimics involve unique 
triple RNA design; the guide strand and a passenger strand made up of two LNA modified strands. 
The miRNA strand sequence is complementary to miRBase annotation. Mimics with the 
fluorescent label (FAM) help to assess transfection efficiency and mimics with biotin label enable 
to isolate targets by RNA pull down. In our study, the mimic did not contain either the FAM or the 
biotin labelling. To summarize, the use of tree RNA strands makes sure that only the miRNA 
strand is incorporated into the RISC complex with no miRNA activity form the two complementary 
strands. 
 
4.1.7 Scratch Test. 
Scratch assay was performed to study cell migration. HLF cells were seeded into 6-well 
dishes in 2 ml complete media and incubated for 24h to create a 70-80% confluent 
monolayer. The cell monolayer was scratched with a p20 pipette tip across the center of 
the wells. This was followed by washing the cells with media twice to remove debris. The 
cells were added with 2 ml complete media with 1% FBS. This was done to limit 
proliferation and growth for additional 48h. The cells were then washed twice with PBS 
and fixed with 3.7% paraformaldehyde for 30 min. The fixed cells were stained with 1% 




Human primers were designed for amplification of target regions in cDNA, genomic DNA 
or bisulphite converted DNA (Table 1). USCS genome browser 




4.2.1. Primer Design- RT-PCR primers 
RT-PCR primers (22-24 bp in length) (Table 1) were designed to span introns or exon-
exon junctions and encompass an amplicon of ~150 bp in regions without SNPs. 
Following designing, the primers sequences were run through BLAT 
(https://genome.ucsc.edu/cgi-bin/hgBlat) for sequence alignment. 
 
4.2.2 Primer  Design- Bisfulphite PCR primers 
To design primers for bisulphite converted sequence, the genomic sequence of interest 
was changed to the predicted sequence after conversion, using find/replace function in 
word. Specifically, 
CG > XG (e.g. AAAGGGCGCGCCCCGGA > AAGGGXGXGCCCCGGA) 
C > T (e.g. AAAGGGCGCGCCCCGGA > AAAGGGTGTGTTTTGGA) 
XG > CG (e.g. AAAGGGXGXGCCCCGGA > AAAGGGCGCGCCCCGGA) 
Since no online tool is available for designed bisulphite PCR primers, multiple primer pairs 
were designed to each loci ensuring that as much complexity was included in the primer 
sequences (as there would be significantly less C present) and avoid long stretches of 
mononucleotide Ts (Table 1).  
Table 1 Primer sequences. Table shows sequence of the primers we used during the project 
including those for bisulphite PCR, RT-PCR and dCas9 selection. 
Loci/PCR 
name 





























RPL19 RT GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA 












4.2.3 Statistical Analysis 
IBM SPSS Statistics Version 23 (IBM Corp,2015) was used for all statistical analyses. 
One tailed and two tailed t-test was performed where appropriate. One tailed t-test was 
used to look at differences in groups in a specific direction whereas two tailed t-test was 
used to study the possibilty of both positive and negative differences.  
 
4.3 Experimental Protocols. 
4.3.1. Extracting RNA. 
Total RNA was isolated from all cell lines using the Invitrogen TRIzol Reagent 
(ThermoFisher) according to the manufacturer's instructions with a few modifications. The 
cell pellet was resuspended in 1 ml of Trizol and left at room temperature for 20 min before 
the addition of 500 µl of chloroform. Following centrifugation, 400 µl of the aqueous phase 
was transferred to a new Eppendorf tube and 320 µl of isopropanol was added. The tube 
was centrifuged for 1h at 11,000 g/4°C and the RNA pellet washed in 70% ethanol. A 
repeated spin step ensured the RNA was washed and the pellet was dried and finally 
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resuspended in DEPC-H20 or TE. RNA concentration was determined using a NanoDrop 
2000 Spectrophotometer (Thermo Scientific) and the RNA was stored at -80°C until use. 
 
4.3.2. Extracting DNA. 
Genomic DNA was isolated by the standard phenol/chloroform extraction. Cell pellets 
were washed with PBS and centrifuged at 1000 rpm for 5 min. The pellets were 
resuspended in 1 ml of Lysis buffer to which proteinase K and SDS was added. This was 
incubated at 37°C overnight on a heat block. The following day, an equal volume of 
phenol/chloroform was added to the cell lysates into phase-lock gel tubes (Prime5) and 
mixed. To separate organic and aqueous phases, centrifugation was performed at 1000 
rpm for 5 min. The phenol/chloroform extraction was repeated 3 times until a clean 
aqueous phase was obtained. Three subsequent phase-lock spins with chloroform only 
were performed. Genomic DNA was precipitated by adding 1 in 10 of the volume of 3 M 
AcNa and 2.5 volumes of 100% EtOH. Genomic DNA pellets were washed once with 70% 
EtOH and air-dried. Dried pellets were resuspended in TE or H2O. The quantity and purity 
of the DNA was determined by measuring absorbance at 260 nm (A260) and 280 nm 
(A280) using a NanoDrop 2000 Spectrophotometer (Thermo Scientific). An A260/280 
ratio of 1.8-2.0, indicates DNA free of contaminating phenol or protein. All genomic DNA 
was stored at -20°C until use. 
 
4.3.3. Making cDNA using random primers for mRNA expression. 
cDNA for gene expression utilized 1 µg of total RNA in a 20 µl reaction volume. RNA was 
first treated with DNase I, Amplification Grade (ThermoFisher) according to the 
manufacturer's instructions. Following the inactivation of DNase I by 25 mM EDTA, the 
RNA in a volume of 11 µl was heated for 5 min at 70°C. Subsequent random primer RT 
was then carried out using M-MLV Reverse Transcriptase (Promega) in a Veriti 96-Well 
Thermal Cycler (Applied Biosystems). An RT-negative control of cDNA synthesis 
(omission of the MMLV RT) was performed to detect possible contamination with genomic 
DNA. Before use in qPCR, the integrity and efficiency of RT conversion was assessed by 




4.3.4. miRNA specific cDNA synthesis and qRT-PCR 
The TaqMan Advanced miRNA cDNA Synthesis Kit (Applied Biosystems) was used to 
generate miRNA compatible cDNA for the miRNA amplification in the HCC cell lines. The 
cDNA synthesis was performed according to the manufacturers’ protocol and included 
four different reaction steps: the poly(A) tailing reaction, adapter ligation, reverse 
transcription (RT) reaction and the miR pre-Amp reaction (Fig.11). Since the Advanced 
assays do not allow for normalization to RNU6B, the reverse primer along with RNU6B 
and RPL19 were “spiked-in” the RT step. Relative expression levels of RPL19 and 
RNU6B were used to check the effciency of the RT reaction. Afterwards, expression 
levels of miR512-3p, miR-518f-5p, miR-520d-5p, miR-525-5p, miR-517-3p and miR-122-
5p were quantified using TaqMan Advanced miRNA Assays (Applied Biosystems) 
according to the manufacturer’s instructions. The qPCR reactions were carried out in 
quadruplicate for each miRNA and endogenous controls on a 96-well plate and amplified 
in a 7500 Fast Real-Time PCR system. 
 
Figure 11 cDNA template preparation. The first step of cDNA synthesis is the addition of 3’-
adenosine tail to the miRNA by Poly(A) polymerase. Poly A tail added miRNA undergoes adaptor 
ligation at the 5’ end. The adaptor serves as the forward-primer binding site for the miR-Amp 
reaction. The third step involves binding of a universal RT primer to the 3’ Poly (A) tail, reverse 
transcribing the miRNA. CDNA is created through reverse transcription. The last step is miR-Amp 
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reaction. This step uses universal forward and reverse primers to increase the number of cDNA 
molecules. 
  
4.3.5. RT-PCR Optimization. 
With the aim of optimizing RT-PCR, reactions were performed in a MicroAmp Fast Optical 
96-Well Reaction Plate using either SYBR green (for mRNAs and pri-miRNA) or 
advanced taqman probes (miRNAs). A template dilution series of 5 µl of 1:10, 1:100 and 
1:1000 was set up so that correlation coefficient slopes and melting curve could be 
generated to ensure reactions worked efficiently. 
 
4.3.6. qRT-PCR deltaCT. 
The delta-delta Ct method (devised by Livak and Schmittgen, 2001) was used to obtain 
the relative fold miRNA/gene expression of the control and HCC samples when 
performing qPCR. Ct stands for the cycle threshold and represented the cycle number 
where the fluorescence produced by the PCR product can be distinguished from the 
background noise. Delta Ct is the difference in Ct values for the gene of interest and the 
housekeeping gene. In this study, the average of RLP19 and ACTB genes was used to 
normalize pri-C19MC and target mRNA gene expression levels. Moreover, we initially 
normalized mature miRNAs to RNU6B. However, RNU6B has been reported to be 
unsuitable for normalization as it is highly variable in HCC and liver samples (Lamba et 
al., 2014; Lou et al., 2015). Therefore, we selected another two control miRNAs as 
normalizers which were less variable. Labma et al. (2014) recommend normalizing 
miRNA against miR-152 and miR-23b in HCC samples, thus we normalized our miRNAs 
not only to RNU6B but also miR-152 and miR-23b. An in-house excel template with all 
the required calculations was used to obtain the Ct values which was in turn used to 
quantify pri-C19MC and mature miRNAs in the HCC cancer cell lines and control liver 
samples.  
 
4.3.7. Bisulphite conversion. 
DNA Methylation Kits from ZYMO Research were used for bisulphite conversion. In 
general, we used 1 µg of DNA as a template and following manufacturers’ protocol. To 
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20 µl of 1 µg DNA, 130 µl of CT conversion kit was added and the reaction was incubated 
in a thermocycler. Binding Buffer was added to a Zymo-Spin IC Column with the 
corresponding collection tubes. Samples were loaded into the columns and mixed by 
inverting the column several times. After centrifuging at 10,000 g for 30 sec and discarding 
the flow-through, washes were performed with 100 µl of M-Wash Buffer and same 
centrifuge conditions. To finish the conversions in which all non-methylated cytosines are 
deaminated to uracil (Fig.12), we added 200 µl of M-Desulphonation buffer to each 
column and incubate at room temperature for 20 min. After the incubation, we centrifuged 
at 10,000 g for 30 sec and repeated the washing step twice, this time, with 200 µl of M-
Wash Buffer. Finally, the columns were placed into a 1.5ml microcentrifuge tube and 
performed a double elution with 10 µl of M-Elution Buffer by centrifuging 11000 g for 30 
sec. BS-converted DNA was stored at -20ºC until use. 
 
Figure 12 Bisulfite Conversion. This technique is widely used to determine pattern of 
methylation in which unmethylated cytosine (C) is deaminated to uracil whereas methylated 
cytosine remains intact. Thymines (T) and guanines (G) are not affected throughout the process. 
During PCR amplification, urcails (U) are recognized as thymines (T) while methylated cytosines 
are recognized as cytosines (as indicated by red squares). This therefore enables to distinguish 
methylated residues from unmethylated residues.  
 
4.3.8. PCR Reactions. 
For standard PCR, we used around 50 ng of genomic DNA or the cDNA equivalent of 50-
100 ng RNA (generally 1 µl of cDNA) as template in a 13 µl reaction using Biotaq Taq-
polymerase (Bioline). For all amplifications using Bisulphite-converted DNA or other 
difficult templates, we utilized hot-start Immolase Taq-polymerase (Bioline) in 13-25 µl 
reactions. All PCRs performed included a non-template negative control for amplification 
41 
 
from contamination sources. For Immolase enzyme-based reactions an initial 
denaturation step of 96°C for 10 min was required for enzyme activation and if the PCR 
was performed for methylation analysis, 45 cycles were required to obtain suitable 
amplification for downstream applications such as sequencing or cloning (Fig.13). 
 
Figure 13 PCR conditions. The PCR conditions with Immolase Taq Polymerase were: one cycle 
of 96°C for 10 min, 45 cycles of 96°C for 30 sec, 53°C for 30 sec and 72°C for 1 min, followed by 
one cycle of 72°C for 7 min. 
 
4.3.9 Cloning of bisulphite PCR products for strand-specific, base-pair resolution 
methylation. 
PCR sub-cloning was performed in T-Vector Systems since some thermostable DNA 
polymerases add a single A nucleotide to the 3’ end of blunt DNA, producing a “sticky-
end” PCR product ideal for 3’ T vector cloning. The A-tailed PCR products were directly 
ligated to the pGEM-T easy vector (Promega) (Fig.14) using ~3.5 µl of PCR product + 
H20, 1 µl (50 ng) of vector, the appropriate amount of ligation buffer and 1 µl of T4 DNA 
ligase. The ligation reaction was left at 4ºC overnight and used later for bacterial 




Figure 14 pGEMT-easy vector Map. Taq Immunolase amplified PCR products were inserted in 
pGEMT-easy vector which contains T7 and SP6 RNA polymerase at a multiple cloning region 
within alpha-peptide coding region of beta-galactosidase. 3’-T overhangs at the insertion sites 
allows efficient ligation of a PCR product into the plasmid as the overhangs provide a matching 
overhang for PCR products. 
 
The ligations were transformed into E.coli competent cells (either JM109s of DH5α) by 
heat shock (30 min in ice, 45 sec at 42°C and 2 min in ice) followed by a growth in LB 
without antibiotic for 30 min-1h shaking at 37°C. The transformed cultures were then 
spread on LB-agar plate with Ampicilin, X-Galactose (Promega) and IPTG (Sigma 
Aldrich) and grown at 37°C overnight. The vector allows for blue/white selection based 
on hydrolysis of β-galactosides. Positive white clones were picked and grown in 50 µl of 
LB-media without ampicillin for an hour. A selection PCR with primers designed to flank 
the T-cloning/multiple cloning sites was performed with 1 µl of the culture acting as the 
template. All appropriately sized amplicons were sequenced by Sanger sequencing using 
M13F or T7 primer located immediately internal to the PCR oligonucleotides. 
 
5. Results. 
5.1 Initial methylation and expression observations in HCC cell lines. 
5.1.1 DNA methylation profiling. 
I initially characterized the C19MC promoter methylation in nine HCC cell lines and 
normal liver samples through bisulfite PCR. We used a placenta control for a partial 
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methylated control since one-allele is methylated. These were dependent on either 
pyrosequencing, direct Sanger sequencing or cloning of individual DNA strands. C19MC 
promoter is silenced in normal liver, hence we used normal liver biopsies as controls. This 
revealed that SNU354, JHH2 and JHH4 were aberrantly unmethylated (<10%) whereas 
Huh7, HLE, HLF and HepG2 were highly methylated similar to normal liver (>70%). 
Statistical analysis showed that Huh7, HLE, HLF and HepG2 were significantly 
methylated like normal liver ( p value 2.39x10-5 ,  <0.05) when compared to SNU354, JHH2 
and JHH4. On the other hand, partial methylation was observed with HepB3 and HuccT1 
(25-40%) (Fig.15A). Pyrosequencing gives the average methylation within an amplicon, 
but we also wanted to look at methylation status of individual DNA strands in HepG2 and 
HLF cells. Using strand-specific cloning approach I confirmed that both the HepG2 and 
HLF promoter is fully methylated on all strands (Fig.15B,C&D). Looking at methylation of 
individual strands in these two cell lines, strands were more methylated in HepG2 than 
HLF (Fig.15C&D), consistent with the C19MC methylation percentage data obtained 
using pyrosequencing (Fig.15A). Statistical analysis, using one tailed t-test, also revealed 
that HepG2 cell line is significantly more methylated than HLF cell line as the p value 
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Figure 15 DNA methylation profiling. A) SNU354, JHH2 and JHH4 were aberrantly 
unmethylated, which is cancer related hypomethylation, whereas Huh7, HLE, HLF and HepG2 
were significantly highly methylated like normal liver, with p value being 2.39x10-5 (less than the 
significance level of 0.05). Also, Hep3B and HuccT1 were shown to be partially methylated. This 
figure was produced with a biological replicate of three, thus the standard error bars indicate how 
the data is spread around the mean value. B) pGEMT PCR was run for the HepG2 cells cloned 
with 350bp insert. Lane 1, 1kb ladder; Lane 2-9 HepG2 PCR product with the correct insert; Lane 
10, Hepg2 PCR product with the wrong insert: Lane 11-15, HepG2 with the correct insert; Lane 
16 positive control; Lane 17 Blank control. The size of PCR products was compared with the 
positive control which was approximately 600 bp. All appropriately sized amplicons were 
sequenced by Sanger sequencing. C) Sequencing data for all 5 CpGs within the C19MC-2 
amplicon showed that six DNA strands were cloned and HepG2 promoter was methylated on all 
strands, indicated by the black circles. D) Similarly, all CpGs were sequenced within the same 
amplicon for HLF revealing that the interval was largely methylated. However, HLF had more 
unmethylated positions than HepG2. 
 
5.1.2 miRNA expression optimizing. 
Next, we wanted to determine miRNA expression in HCC cell lines. Previous studies in 
the Monk laboratory observed reactivation of miR-517, miR-525 and miR-520h in JHH2 
and SNU345 cells. This is consistent with the hypomethylation observed. Standard 
microRNA real-time PCR assays normalized to RNU6B were used to obtain these results. 
I initially needed to optimize amplification, thus using Taqman “Advanced” miRNA assays 
I quantified more C19MC-derived miRNAs in the same sample cDNA. The miRNA 
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expressions were normalized to miR-152 and miR-23b as well as RNU6B spike-in, due 
to the reasons stated previously (Lamba et al., 2014; Lou et al., 2015).  
In addition to amplifying mature miRNAs, I have designed qPCRs to the pri-C19MC with 
the aim of measuring the unprocessed transcript. To achieve this, I designed primer sets 
in single copy regions of the C19MC, near miRNA sequences (miR-518 and miR-520d). 
This was difficult since the structure of the locus is made up of SINE-miRNA blocks. 
Primers of 22-24 bp in length were designed to amplify ~150 bp without underlying SNPs. 
The sequences were subjected to BLAST and BLASTn to make sure they were single 
copy. Using standard PCR, and visualizing on an agarose gel, we confirmed the efficiency 
of PCR amplification. For qPCRs, reactions were carried out in triplicate in a MicroAmp 
Fast Optical 96-Well Reaction Plate using SBYR Green. A dilution series of template (5 
µl of 1:10; 1:100 and 1:1000) was amplified to ensure the reactions worked efficiently as 
indicated by the correlation coefficient slope of –3.08 (a specific and highly efficient qPCR 
has a ratio of –3.3) for pri-miR-518 and –3.4 for pri-miR-520d (Fig.16A,B&C).  





Figure 16 Optimizing qPCR. A) The standard curve was created by setting a serial dilution of 
template and amplifying with qPCR. The correlation coefficient slopes obtained were –3.08 and -
3.4 for pri-mir-518 and pri-mir-520d, respectively. B) The blue amplification plots appeared to be 
clear indicating that difference in normalized fluorescence is large hence the density range is 
appropriate. C) The melt curves measure the amount of fluorescence and are normally produced 
after the amplification cycles are completed.  
 
5.1.3 miRNA expression profiling. 
Taking the advantage from the previous studies in the Monk lab, in this study we assessed 
expression of miR-512-3p, miR-518f-5p, miR-525-5p, miR-520d-3p and miR-517c-5p in 
nine HCC cell lines. It was essential to investigate miRNA expression with the aim of 
assessing the links between aberrant DNA hypomethylation in HCC cell lines and re-
activation of oncogenic miRNAs. C19MC miRNAs are not expressed in normal liver. To 
discriminate between a sample with poor quality RNA and tissue-specific absence of 
expression I confirmed miRNA expression using a previously described liver specific 
miRNA. I chose miR-122-5p as the control miRNA because this non C19MC miRNA is 
not only highly expressed in liver but also is downregulated in cancer (Jopling, 2012). 
Based on the miR-122-5p expression profile Liv5 was used as the control cell line. On the 
other hand we used the placenta trophoblast JEG3 cell line as the control for C19MC, as 
these cells highly express the miRNAs from this cluster. miRNA expressions were 
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normalized to the average of miR-152 and miR-23b as well as RNU6B for reasons stated 
previously. 
 
miR-512-3p was only detected in JHH2 following both control miRNA and RNU6B 
normalization (Fig.17A&B).  On the other hand, miR-518f-5p was detected in all HCC cell 
lines with highest in SNU354 (Fig.17C). When normalized to RNU6B, miR-518f-5p 
expression was less than when normalized to two control miRNAs and was not detectable 
in JHH2 and HepG2 (Fig.17D). Expression of miR-525-5p was observed in JHH4, 
SNU354 and HLF, for both control miRNA and RNU6B normalization (Fig.17E&F). MiR-
520d was expressed in JHH4, SNU354 and HLF when normalized to miRNAs (Fig.17G) 
however, it was detected in JHH2 when normalized to RNU6B (Fig.17H). miR-517c-3p 
activity was observed in SNU354 and HLF with a modest expression in JHH4 (Fig.17I&J).  
The control miR-122-5p was shown to be detected in most HCC cell lines with highest 
levels in the normal liver control, as expected. miR-122-5p activity was not detectable in 
JHH4 (Fig.17K&L).  
 
Overall, we detected similar miRNA activity when normalized to both two control miRNAs 
or RNU6B (note, the scale of the y-axis changes due to the levels of endogenous 
controls). We expected to detect miRNA expression in the unmethylated cell lines (JHH2, 
JHH4 and SNU354) since unmethylated promoters facilitate expressions. However, in 
some cases such as miR-512-3p, we did not detect miRNA expression in all the 
unmethylated cell lines. It is also interesting to note that some miRNAs were expressed 
highly in HLF although this cell line has a partially methylated C19MC promoter. Finally, 
despite detecting varying amounts of these miRNA in the HCC lines, their abundance 
was several magnitudes less the the endogenous levels of the positive control, the 
placent cell line JEG3. 
 
















































































Figure 17 miRNA expression profiling. Standard miRNA real-time PCR assays normalized to 
control small RNAs; the average of miR-152 and miR-23b or RNU6B, respectively. These graphs 
were produced with a technical replicate of three and a biological replicate of one, therefore 
standard error bars could not be added. 
 
5.2 Epigenetic manipulations with small molecule inhibitors. 
5.2.1 Optimizing 5-aza-DC treatments. 
Small molecule inhibitors, 5-aza-DC and TSA were used in this study to demethylate the 
methylated HCC cell lines. Before we could assess the inhibitory effect of small molecule 
drugs on DNA methylation in our HCC cell lines, I needed to determine the general toxicity 
and consequence on cell replication for 5-aza-DC treatment. For this I determined 
proliferation by counting cells every day for a 5-day time course during which the cells 
were exposed to different concentrations of 5-aza-DC. Following literature searches, 
several publications suggested that the working concentration, to result in global 
demethylation, was between 1-10 µM (Pall et al., 2008; Zhang et al., 2016). For total cell 
counts I determined the percentage mean number of cells for each concentration. When 
compared to controls, the percentage mean for the lowest concentration, 0.5 µM, 
remained stable at approximately 80% of controls, suggesting that there may have been 
an initial low-level toxicity with a decrease of 20%. As the concentration increased, there 
was a proportional effect on cell counts at 24h, after which the cells maintained at this 
number. In general, the number of cells obtained from 1 µM, 2.5 µM and 5 µM incubations 
after 72h-96h were approximately 50% less of the untreated controls. The most severe 
effect was for the highest concentration 10 µM, for which there were 85% less cells 
compared to the control (Fig.18A). 
 
Rather than relying on cell count alone, I further assessed the effect of 5-aza-DC 
treatment using MTT assays, a colorimetric test to determine metabolic activity. Using the 
same drug dilutions and similar exposure time, I observed that increased concentration 
of 5-aza-DC caused an increase in cell death, with the largest effect recorded for 10 µM. 
This was consistent with the cell count data. Despite the sharp decrease in viability 
observed at 10 µM, and the relatively large standard deviation (indicating the variance for 
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each replicate), the IC50 value, that is, the concentration of compound which exhibits 
50% cell viability, was determined to be 10 µM (Fig.18B). 
Based on classical toxicology, 10 µM for a minimum of 3 days should be selected, 
however our final experimental read out is the total decrease in C19MC promoter 
methylation. To address this, I extracted DNA from the cells exposed to various 
concentrations of 5-aza-DC and used them for bisulphite conversion for C19MC PCR. 
The sequencing results revealed a reduction in global methylation and showed that the 
C19MC promoter region was ~30% demethylated compared to untreated control cells. I 
also performed statistical analysis which showed that cell death occured the most at 10 
µM (p values <0.05). Based on these observations, I finally selected the 5-aza-DC 






Figure 18 Optimizing the concentration and duration for 5-aza-DC.  These figures were 
generated with a biological replicate of three and standard error bars represent the variance for 
each replicate A) The percentage mean number of cells was calculated for each concentration 
and each time period. Comparison of percentage mean number of cells revealed higher 
concentration of 5-aza-DC resulted in less cells, with 10 µM causing the highest number of cell 
death compare to untreated controls. This was statistically shown to be significant as the p value 
obtained from one tailed t-test was 0.040 (<0.05) B) MTT assay is a colorimetric assay uses 
reduction of a yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, or MTT) to measure cellular metabolic activity as a proxy for cell viability. The 
absorbance value is proportional to cell number. After 72h, the IC50 was reached using 5-aza-
DC at 10 µM which was again shown to significantly result in the highest cell death with a p value 
of 0.033 (<0.05). 
 
5.2.2 Methylation profiling following combined 5-aza-DC and TSA experiments. 
We treated HLF cells with 5-aza-DC to inhibit methylation, TSA to inhibit histone 
deacetylation and with both to obtain maximum transcription from the C19MC promoter. 
We could detect residual expression for some C19MC-derived miRNAs in HLF. However, 
the expression was not to the levels of unmethylated SNU354 cells or endogenously 
expressing JEG3 control cells, suggesting that all auxilary factors were present yet 
expression was limited by the promoter hypermethylation. As a result, we selected HLF 
cell line for the drug experiment and all future experiments. To address whether 
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demethylation was induced upon drug treatment, I extracted DNA from the cells exposed 
to the drugs for 3 days, 7 days and 10 days. I also extracted DNA from the untreated 
control cells which enabled us to assess the impacts of the drugs on methylation. The 
extracted DNA was used for bisulfite conversion for C19MC PCR. Sequencing results 
showed that the control cells were fully methylated whereas 10-20% of demethylation 
was achieved in the cells treated with 5-aza-DC and 5-aza-DC plus TSA for 3 days. The 
cells exposed to the drugs for 7 days were 15-20% demethylated. On the other hand, 20-
30% demethylation was observed from the cells exposed to 5-aza-DC and 5-aza-DC plus 
TSA for 10 days. We did not observe demethylation in cells treated with TSA only, 
suggesting that histone acetylation did not affect DNA methylation. To summarize, our 
results suggested that demethylation was achieved in our HLF cells treated with 5-aza-
DC as well as combined 5-aza-DC and TSA. Treating the cells with the drugs for 10 days 
significantly resulted in more demethylation than 3 days and 7 days (p value<0.05) 
(Fig.19). 
   
 
Figure 19 Methylation status after the drug treatment. Left side, before the treatment, we 
showed that HLF cell line is methylated similar to normal liver. HLF cells were then exposed to 5-
aza-DC, 5-aza-DC plus TSA for 3 days, 7 days and 10 days. TSA was added 24h before 
harvesting the pellets. Following, DNA extraction, bisulfite conversion and C19MC2 PCR, the 
samples were sequenced to assess the C/T ratio. Right side, the results showed demethylation 
54 
 
following treatment with 5-aza-DC and 5-aza-DC plus TSA.  Treating the cells with the drugs for 
10 days significantly resulted in more demethylation since the p value was found to be 0.001, with 
a two-tailed t-test. TSA alone did not affect methylation suggesting that methylation was not 
affected by histone acetylation. Standard error bars were not applicable since this experiment 
was biologically repeated once. 
 
5.2.3 miRNA reactivation in 5-aza-DC and 5-aza-DC plus TSA treated cells . 
Once we confirmed that 5-aza-DC and TSA treatment resulted in demethylation of the 
C19MC promoter in HLF, we next wanted to determine if demethylation was sufficient to 
massively reactivate our miRNAs. Following RNA extraction from the drug treated HLF 
cells, cDNA was made and C19MC-derived miRNAs in the cDNA were quantified by using 
Taqman “Advanced” miRNA assays. We also assessed the expression of pri-C19MC 
transcript in control and treated cells. For miRNA qPCRs, reactions were carried out in 
triplicate in a MicroAmp Fast Optical 96-Well Reaction Plate and normalized to miR-152 
and miR-23b as well as RNU6B.  The quantification of of pri-C19MC was normalized to 
RPL19 and ACTB. 
 
The qPCR results revealed that the miRNAs were lowly expressed in the untreated 
control cells but were readily reactivated in 5-aza-DC and 5-aza-DC plus TSA treated 
HLF cells, initially detectable following 3 days treatment, and maximal at 10 days. In 
addition, we showed that pri-C19MC long-coding RNA was also re-expressed upon 
treatment. Logarithmic scales were empolyed to visualize the resulting data as induction 
of C19MC miRNA expression was massive comapred to the untreated controls. Following 
treatment for 10 days, miR-512-3p significantly had the highest increase in fold among all 
miRNAs when normalized to both control miRNAs or RNU6B (p value<0.05)(Fig.20A&B). 
In addition, h igh levels of miR-518f-5p, miR-525-5p, miR-520d-5p and miR-517c-3p 
expression were observed and there was no expression in TSA-only treated cells 
(Fig.20C-J). In general, miRNAs significantly had higher expression in 5-aza-DC plus TSA 
treated cells when compared to 5-aza-DC only, which was also greater for the 10 days 
treated cells when compared to only 3 days (p values <0.05). Cells exposed to TSA only 





























































































































Figure 20 miRNA reactivation normalized to two control miRNAs and RNU6B. Standard 














































































































































































23b or RNU6B, respectively, was used to obtain these results. All 5 miRNAs were not expressed 
in control HLF cells and were reactivated in drug treated cells. One-tailed t-test results revealed 
that mir-512-3p significantly had the highest increase in fold among all miRNAs with the p value 
of 2.99x10-6. Overall, miRNA expression was significantly higher in the combined 5-aza-DC and 
TSA treated samples (p value 0.03) for 10 day exposure (p value 2x10-4). Because these graphs 
were produced with a technical replicate of one but biological replicate of one, standard error bars 
could not be included to show the distrubition of the data around the mean value. 
 
5.3 Epigenetic manipulations with dCas9-TET strategy. 
5.3.1 Designing crRNA for dCas9-TET experiments. 
Treatment with small molecule inhibitors presumably affected the whole genome, 
including C19MC promoter. In order to study C19MC specifically, we wished to use the 
dCas9-TET strategy. Before transfecting HCC cells with the pLV hUbC-dCas9-TET1-
T2A-GFP construct I designed the crRNAs to the C19MC promoter interval. The DNA 
sequence of the C19MC promoter CpG islands was obtained from the UCSC genome 
browser and mapped all CpG dinucleotides. Using Cas9-target function of UCSC browser 
I identified 22 different gRNA/crRNA sequences which were high scoring using 3 
algorithms (MIT guide specificity, efficiency defined by Doench et al. 2016 and Moreno-
Mateos in vitro score) located throughout the promoter interval. I then selected the nine 
best distributed gRNAs throughout the interval mapping to both DNA strands, all 
possessing the NGG PAM sequence (Table 2). Since the promoter consists of five 
imperfect ~50 bp repeats, I also designed a crRNA for this as it may allow for multiple 
interactions using a single crRNA sequence. Importantly, the bisulphite PCRs that would 
allow for methylation to be quantified are located in the center of the CpG island, 
overlapping 3 crRNAs. 
Table 2 gRNA sequences. The table shows the sequences of nine gRNAs which possess the 
NGG PAM sequence as well as the repeat sequence 
            gRNAs     Sequence 
1. gRNA GTGTTGATTCTTGCGGAACA 
2. gRNA CCCAAGCGGGTACATTTGCC 




4. gRNA AGGTGTGCTCCCAGGGTCTCCACATCCCTAA 
 
5. gRNA CCGCAAGGCTGGCCTCTTTA 
6. gRNA CTGTTTCcgCTGCcgGcgTC 
7. gRNA TGGACcgAGGTCTCTAGAGCTGC 
8. gRNA TGCGACAATCTTCCGGTGCC 






5.3.2 Comparing methodologies for introducing dCas9-TET-CD constructs into 
cells 
For the initial delivery of the dCas9-TET-CD-T2A-GFP constructs I used lipofectamine. 
This resulted in ~10-20% GFP positive cells. However, the GFP positive cells did not 
survive for the FACs selection and all cells subsequently died in culture. The control 
pMax-GFP plasmid had a higher efficiency with 50% green suggesting that the size of the 
dCas9-TET plasmid which is >14 kb might be the limiting factor (Fig.21A). Next, we 
transfected the cells with using PEI (Fig.21B). Unfortunately, cells failed to survive again. 
 
We also used JetPRIME transfection reagent but despite many attempts using these 
reagents we failed to efficiently deliver the plasmid into the cells. Therefore, we could not 
obtain sufficient positive cells for FACs. The same plasmid is available in the Monk 
laboratory with the GFP gene replaced with a puromycin gene to allow for antibiotic 
selection. Again, following Lipofectamine transfection, 2 rounds of puromycin selection 
for 4 weeks failed to result in stable colonies (and additional replicated became infected 
and died). Finally, we changed strategy and used the lentiviral pLV hUbC-dCas9-Tet-
T2A-GFP and Fuw-dCas9-TET-CD plasmids. These plasmids are smaller from Addgene 
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Figure 21 dCas9-TET Experiments. We used Lipofectamine, PEI and JETPRIME transfecting 
reagents to deliver the dCas9-TET-CD construct into HLF cells. A) We did not observe green cells 
with GFP containing construct. However, treatment with a smaller GFP-pMax vector resulted in 
high number of positive cells. This suggested that our construct might be too big for an efficient 
delivery. B) We then added puro to our construct and put our cells in puromycin media following 
transfection. Unfortunately, our cells did not survive. C) We changed strategy and used a lentiviral 
transfection. This construct lacked the T2A-selection gene, making it significantly smaller and 
included LTR repeat sequences. The virus utilizes these LTR repeats to stably intregrate the DNA 
into the cell genome.  
 
5.3.3 TET Lentiviral introduction of dCas9-TET constructs into cells. 
Since our transfection approach has failed after numerous attempts we switched to using 
dcas9-TET lentivirus infections. Following 48h of incubation with the virus, cells were 
trypinised and divided into two aliquotes, one for DNA/RNA extraction to ensure the cells 
were positive for dCas9 plasmid, the other to continue growing. Amplifying single 
transfected cells with dCas9 primers resulted in bright bands. PCR positive cells were 
expanded and divided into two further aliquotes, one to generate stable cell lines and the 
60 
 
other reinfected with the lentivus one more. Following PCR confirmation that the cells 
contained the dCas9 construct, both single and double infected cells were expanded to 
generate monoclonal stable cells. The double infected cells were subjected to FACs to 
ensure single cells were dispensed into each well of 96 well plates for subsequent 
expansion (Fig.22). Of the 380 indiviudal cells plated, 44 gave rise to colonies. Duplicate 
plates were generated to allow for both PCR selection and continued culture. All tested 
colonies were PCR positive and selected for continous expansion (Fig.23A&B). In 
addition to confirming the presence of the dCas9-TET-CD construct by PCR, the function 
and copy-number of the plasmid was needed to ensure functional protein was being 
produced in adequate amounts. However, due to having limited time I could not perform 
these experiments. 
 
Figure 22 Schematic diagram of dCas9-TET lentiviral infection strategy. The work-flow 
represents the tissue culture procedure carried out for infecting HLF cells with dCas9-TET 
lentiviral. Initially, the cells were seeded in 6-well plates and infected with lentiviral. Following 
incubation, 50% of these cells were seeded in 10 cm dishes and half were harvested for dCas9 
PCR. After confirming dCas9 was present in the cells, we infected the cells for the second time. 
Again, some of these cells were maintained in culture and some harvested for a second dCas9 
PCR. One dish of double infected cells was subjected to FACs analysis. Using appropriate FAC 
gating, single cells were added to each well of a 96-well plates with “A1” containing 100 cells as 
a bulk control. Following three weeks of culture, colonies were obtained from some of the single 
cells. These stable cells were used for a final dCas9 PCR to ensure they were positive cells and 
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Figure 23 Representative gel Image of dCas9 PCR. A) Both double and single infected HLF 
cells were subjected to PCR with dCas9 primers to validate dCas9 integration. PCR amplicons 
were obtained from HLF cells with both first and second rounds of infections suggesting that the 
cells were positive for dCas9. B) The second gel image is an example showing the bands obtained 
from dCas9 PCR on the expanded monoclonal cultures. Along with the dCas9 PCR,  Xchr primers 
were used to show the presence of genomic DNA. 
 
5.4 miRNA mimic experiments. 
5.4.1 Validating miR-512-3p over-expression. 
The miR-512-3p was consistently re-expressed in our 5-aza-DC experiments and I 
therefore selected this miRNA to over-express using miRNA mimic technology. HLF cells 
were transfected with 50 nM and 500 nM of the mimics for 48h. Subsequently, extracted 
RNA was used for miRNA Advanced cDNA synthesis. To ensure over-expression was 
specific for miR-512-3p, qRT-PCR was performed not only for miR-512-3p but also for 
fellow C19MC-derived miR-518f-3p and normalized to the average of miR-152 and miR-
23b in control cells, cells transfected with a C. Elegans mimic (as a scrambled control) 
and cells transfected with miR-512-3p mimic. We did not detect miR-512-3p expression 
in either control cells as expected. The cells transfected with miR-512-3p mimic had 
higher expression using 500 nm than with 50 nM. The over-expression levels obtained 
using 500 nM were less than the endogenous amounts observed in the control JEG3 
cells, suggesting that we had not saturated the HLF cells with mimic and that functional 




Figure 24 mir-512-3p over-expression through mimic transfection. HLF cells were 
transfected with 50 nM and 500 nM of miRNA C. Elgans or mir-512-3p mimic. Two days post-
transfection RNA was extracted and used for miRNA cDNA synthesis. Expression of mir-512-3p 
was compared to the average of control miRNAs and compared with endogenous levels in the 
placenta-derived JEG3 cells. Two-tailed t-test revelaed that significantly higher mir-512-3p 
expression was detected with the cells treated with mir-512-3p mimic when compared to 
untreated control cells and cells treated with C.Elegans control mimic (p value  0.001). This graph 
was generated with a technical repeat of three and biological repeat of one therefore standard 
error bars were not applicable. 
 
5.4.2 Impacts of miR-512-3p over-expression on cell migration. 
To determine whether miR-512-3p over-expression had any potiential oncogenic effects, 
we performed scracth tests to monitor the cell invasion capacity. In cells 2 days post-
transfection with 500 nM mimics, the resulting confluent cell monolayer was scratched 
and the cells were put in only 1% FBS containing media to ensure they could no longer 
divide (thus separating the effects of proliferation from migration). After 5 days in culture, 
cells were visualised under a light-phase microscope and 10 field of view images 
recorded. Subsequently 3 measurements per field of view were recorded at predefined 
locations (Fig.25A,B&C). In total, 30 measurements were taken per replicate and the 




In general, the average distance from three plate condtitions was 9.14, 9.22 and 5.53 
(arbitrary units, AU) for non-transfected control, C. Elegan miRNA and miR-512-3p 
mimics respectively. We performed a T-test with paired two sample for means in SPSS 
and compared the significance of cell invasion (for the mean of replicates) between 
control and miR-512-3p mimic as well as miRNA control mimic and miR-512-3p mimic. 
Our findings suggested that miR-512-3p mimic significantly promoted cell invasion when 
compared to the control and miRNA control mimic, with p values being less than the 
significance level 0.05 (6.78x10-20 and 1.19x10-22)(Table.3). 
Table 3 Statistical Analysis. The table represents the results obtained from statistical analysis, 
including mean, variance and p values. T-test was calculated for paired two sample for means in 
order to compare data obtained from miR-512-3p with control and C. Elegan control respectively. 
p value (red) was checked to assess significance (p value less than 0.05). The mean of replicates 
was compared to obtain the p value. 
t-Test: Paired Two Sample for 





Mean 9.14 5.53 9.23 
Variance 5.47 4.31 4.49 
Observations 90 90 90 
Pearson Correlation 0.12   0.18 
Hypothesized Mean Difference 0   0 
df 89   89 
t Stat 11.65   13.04 
P(T<=t) one-tail 6.78E-20   1.19E-22 
t Critical one-tail 1.66   1.66 
P(T<=t) two-tail 1.36E-19   2.37E-22 





















Figure 25 Cell Invasion Assay. Scratch test was performed to assess cell invasion in (A) 
untransfcted control cells, (B) C. Elegans miRNA control and (C) mir-512-3p mimics. The red 
stippled lines represent gap borders and the size bars represent the average gap distance 
obtained for each three plate conditions. The gap remained open with the untransfected control 
cells and cells transfected with C.Elegans miRNA control mimic (9.14 and 9.22 AU respectively). 
On the other hand the gap was almost closed with cells treated with the mir-512-3p mimic (5.53 
AU). 
 
Thus, the results showed that mir-512-3p over-expression significantly promoted cell 
invasion when compared to control cells and miRNA mimic control (p value<0.05) 
(Fig.25A, B&C, Table 3).  As cell invasion has a crucial role in metastasis it is one of the 
hallmarks of cancer. Therefore, our results indicated the oncogenic properties of mir-512-






6.1 miRNA expression profiling. 
C19MC miRNA cluster is the largest miRNA cluster that has been detected in human 
genome and consists of approximately 46 mature miRNAs (Flor and Bullerdiek, 2012) 
which have been reported to have roles in tumorigenesis (Veronese et al., 2010; Ward et 
al., 2014; Rui et al., 2020). Preliminary studies in the Monk lab observed reactivation of 
miR-517, miR-525 and miR- 520h in JHH2 and SNU345 cells which is consistent with the 
C19MC promoter hypomethylation observed. Moreover, Pang et al. (2014) showed that 
miR-525-3p is often upregulated in HCC tissues and regulated tumor migration and 
invasion via downregulating the expression of ZNF395. This zinc finger gene is 
responsible for activating several cancer-associated genes, including MACC1, PEG10, 
CALCOCO1, and MEF2C (Jordanovski et al., 2013). Another publication reported that 
miR-520h had significantly altered expression in HepG2 cells when compared to normal 
liver tissues (Sun et al., 2016). According to the results, HDAC1 was negatively related 
to the expression of miR-520h, suggesting this interaction had important roles in 
prognosis of HCC. During the course of this study, Rui et al. (2020) showed that 
upregulation of miR-512-3p and miR-519a-5p was associated with poor survival, 
suggesting that these two C19MC miRNAs promote oncogenic pathways in HCC. 
 
Here I have assessed the expression of miR-512-3p, miR-518f-5p, miR-525-5p, miR-
520d-5p and miR-517c-3p.  I initially quantified these C19MC derived miRNAs nine HCC 
cell lines to determine the association between their expression and promoter methylation 
status. It was also crucial to look at miRNA expression before 5-aza-DC and TSA 
treatments in terms of confirming that changes in miRNA expression observed were 
solely from the drug treatment. Our results suggest that the C19MC-derived miRNAs were 
predominatly expressed in the unmethylated HCC cell lines, with the exception of HLF 
which was detectable in varying degrees in the cell lines.  However, it is important to note 
that not all unmethylated cells had miRNA expression. Thus, we hypothesized that more 
epigenetic signals, such as acetylation and chromatin modification, or transcription factors 




More interestingly, we showed that some miRNAs had detectable expression in HLF cells. 
Our methylation studies revealed that this cell line has a hypermethylated C19MC 
promoter (being ~70% methylated). In-depth evaluation of the strand specific methylation 
in HLF cells represented that some individual CpG positions were unmethylated. 
Therefore, methylation-sensitive transcription factors might be able to bind to this interval 
in a sub-population of cell, facilitating transcription (Fig.25). However, more complicated 
scenarios may explain the discrepancy between expression and observed promoter 
methylation. Recently translocation within the C19MC domain have been shown to result 
in fusions which link active promoters with the C19MC miRNA cluster. In this case the 
methylated C19MC promoter would no longer be distal to the miRNA cluster and would 
not exert any regulation of their expression (Fig.26). This is the case for 19q13.4 
translocations that selectively activate C19MC miRNAs in thyroid adenomas (Nguyen et 
al., 2017). Additional studies have shown that fusions between the C19MC and the 
TTHY1 promoter (an embryonic chloride channel protein) facilitate C19MC miRNA 
expression in embryonal tumors with multilayered rosettes (ETMRs) (Kleinman et al., 
2014). Sin-Chan et al. (2019) suggested that C19MC may promote or maintain a primitive 
neural/embryonic epigenetic cell phenotype in ETMRs. Moreover, their study suggested 
that a C19MC-LIN28A-MYCN oncogenic circuit controlled by hijacked super-enhancer 
may be a therapeutic vulnerability in ETMRs (Sin-Chan et al., 2019).  
 
Another possibility is that transcription factors might bind to a different promoter which is 
hypomethylated (Fig.27). Normally, TFs regulate gene expression by binding to gene 
promoter regions or to distal regions, enhancers. Moreover, TFs may bind to DNA 
indirectly through interacting with another TF even though by definition TFs possess DNA 
binding domains (Dekker and Heard, 2015). 
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Figure 25 Expression with methylation. As mentioned before, methylation results in gene 
silencing. However, in one of our methylated HCC cell lines, HLF, we still detected high miRNA 
expression. Our strand-specific experiments showed that some DNA strands were unmethylated 
in HLF. This methylation might not be sufficient enough for silencing. Moreover, transcription 
factors might be binding to unmethylated and/or less methylated sites resulting in expression. 
 
Figure 26 Translocations in cancer. Translocations are pathogenic events in cancer. In our 
case, translocation of a methylated region with an unmethylated region (for instance translocation 
of methylated C19MC with unmethylated TTHY1 promoter) could have facilitated transcription as 




Figure 27 Alternate transcription start site.  TFs could be binding to a different promoter that 
is revelaed if the intergenic C19MC interval is hypomethylated, allowing transcription initiation 
from a downstream position. 
 
6.2 Epigenetic Manipulations with small molecule inhibitors 
Epigenetic changes are known to disrupt gene function and in cancer epigenetic changes 
include hypermethylation of the CpG islands in the promoter regions, global DNA 
hypomethylation, chromatin modifications and loss of imprinting (Hatziapostolou and 
Iliopoulos, 2011; Mouthino and Esteller, 2017). The involvement of miRNA epigenetic 
regulation in cancer was first demonstrated by using an epigenetic drug, 5-aza-2'-
deoxycytidine (5-aza-DC) (Saito et al., 2006). 5-aza-DC is a commonly used small-
molecule that inhibits DNMT1 and DNMT3 (Fig.28). Epigenetic manipulations are widely 
used not only to improve our understanding of how these modifications regulate 
transcription and drive phenotypes (such as cancer), but also for their potential 
therapeutic use (Holtzman and Garsbach, 2018). 
 
Figure 28 Mechanism of methylation inhibition by 5-aza-DC. This drug prevents maintenance 
methylation by trapping DNMTs to methylated C. This reduces cellular DNMT levels whic in turn 
results in reduced methylation and global hypomethylation  
 
The characterization of DNA methylation revealed that the C19MC promoter in HLF cells 
is fully methylated and therefore was an ideal region to test the sensitiveness to 
demethylating agents, such as 5-aza-DC, to induce global demethylation. After 
determining the optimum concentration of 5-aza-DC for my HCC cells, which was 10 µM 
for a minimum of 72h, I exposed the cells to 5-aza-DC for 3-10 days.  In some cases, 
treatment with 5-aza-DC was sufficient to result in transcription, but additional induction 
of expression was observed with the addition of TSA, a histone deacetylase inhibitor.  
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Treating cells with the drugs for 3 days and 10 days resulted in 10-20% and 20-30% 
C19MC promoter demethylation, respectively. These results suggest that, in addition to 
the reported global demethylatation induced by 5-aza-DC, the normally methylated 
C19MC promoter was also sensitive to this small molecule inhibitor.  
 
Synthetized 40 years ago, the DNMT inhibitor 5-aza-DC is not only widely used in 
research but also in clinics for the treatment of malignant diseases. This agent has an 
effective anti-metabolic activity on tumor cells, primarily in the setting of acute myeloid 
leukemia (AML). It is unknown if the anti-cancer effects of 5-aza-DC are due to epigenetic 
remodeling or via its toxic effect at high dosage. There is evidence that 5-aza-DC inhibits 
DNA methylation and interferes with metabolic circuitries (Bezu et al., 2019). Moreover, 
in vitro studies in various solid tumor models have revealed that its main anti-tumoral 
impact is by increasing cancer cell lysis (Weber et al., 1994; Almstedt et al., 2010; 
Krishnadas et al., 2014). However demethylating effect of 5-aza-DC on genomic DNA 
might be restricted to specific regions with some regions not being affected (Tabolacci et 
al., 2016). It is possible that 5-aza-DC could be used to treat HCC through inhibiting DNA 
methylation and reactivation TSGs, however due to the lack of specificity, and possible 




6.3 miRNA reactivation upon global demethylation. 
After confirming demethylation was induced in HLF cells using 5-aza-DC and TSA, we 
looked at miRNA activity to see if this resulted in miRNA reactivation. In comparison to 
the initial miRNA expression profiling, all miRNAs were reactivated upon drug treatment. 
Combination of 5-aza-DC and TSA resulted in higher expression than 5-aza-DC on its 
own. In addition, we observed higher miRNA expression in cells following longer exposure 
to the drug, with 10 days treatments having consistently higher expression compared to 
3 days. This is consistent with the observation that treating cell for 10 days resulted in 
more demethylation than for 3 days. Therefore, our results suggested a direct link 




As mentioned above, all tested miRNAs were reactivated following drug treatment. 
However, expression levels of each miRNA were different even though these miRNAs 
are all derived from the same long non-coding RNA molecule. miRNAs are initially 
transcribed as pri-miRNAs and are then processed into pre-miRNAs by Drosha. Pre-
miRNAs are exported and processed in the cytoplasm by Dicer, giving rise to mature 
miRNAs. Drosha and Dicer are crucial for processing of intermediates to mature miRNAs. 
More importantly, these enzymes introduce variations in miRNAs abundance through 
preferential processing (Fig.29) (Tijsterman et al., 2004; Kim and Nam, 2006; Lee et al., 
2006; Vaz et al., 2013) so that differential expression may occur in which some have 
higher abundance than the others.  
 
Figure 29 DROSHA/ DICER processing. miRNAs are initially processed as pri-miRNAs. Pri-
miRNAs are then processed into pre-miRNAs by Drosha, in the nucleus. Exportin 5 exports pre-
miRNAs into the cytoplasm where pre-miRNAs are processed into mature miRNAs by Dicer. 
Therefore, Drosha and Dicer are crucial for processing intermediates to mature miRNAs and 
introducing variations in miRNAs. This means that miRNAs that are processed from the same 
precursor might be differ in miRNA processing. 
  
Additionally, each miRNA may have a different number of targets. A single miRNA can 
bind to several target mRNAs and several miRNAs can bind to a single target (Lewis et 
al., 2003; Vaz et al., 2013), all of which affects free miRNA within the cell.  miRNAs with 
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more targets may have a lower free miRNA levels than those with less targets (Yu et al., 
2007). For instance, our MiRDB research showed that miR-525-5p and miR-520d-5p 
have 808 and 2404 predicted targets respectively whereas miR-512-3p has 521 predicted 
targets.  In fitting with this theory, I observed higher expression of miR-512-3p than miR-
520d-5p and miR-525-5p, although it is not true for all C19MC-derived miRNAs. 
Therefore, more experimental and computational approaches are essential to study the 
association between miRNA expression and number of targets, as well as the role of 
‘sponge’ RNAs. Sponge transcripts are generally non-coding and also known as 
competing endogenous RNA in humans. Ebert and collogues (2007) revealed that miRNA 
function was lost due to the presence of miRNA sponges which also increased the levels 
of endogenous targets. The H19 imprinted non-coding was one of the first molecular 
sponge reported. The H19 trancript inhibits miRNA let-7 and is associated with human 
genetic disorders and cancer (Gabory et al., 2010; Gao et al., 2014). Previous data 
suggest that miRNA sponges regulate miRNA activity in many eukaryotes, including 
plants (Franco-Zorrilla et al., 2007) and mammals, as well as tumor biology (Poliseno et 
al., 2010; Cesana et al., 2011; Karreth et al., 2011; Tay et al., 2011; Sumazin et al., 2011). 
Poliseno et al. (2010) studied the functional association between the mRNAs produced 
by the PTEN tumor suppressor gene and its pseudogene PTENP1. They found that 
PTENP1 regulates cellular levels of PTEN, playing a growth-suppressor role, which is 
often lost in human cancer.  Overall, their findings showed that pseudogenes may play a 
role in tumorigenesis by fine tuning miRNA-mRNA interactions (Poliseno et al., 2010). In 
subsequent systematic screen (Sumazin et al., 2011), a post-transcriptional regulation 
network was found to have more than 248,000 miR-mediated interactions, 7000 of these 
acting as miR sponges and 148 having non-sponge interactions. This network was shown 
to regulate established oncogenic pathways in glioblastoma through mediating drivers of 
tumor initiation, such as PTEN, PDGFRA and RB1 (Sumazin et al., 2011).  
 
Therefore, it is possible that these C19MC miRNAs have different abudance levels and 
target activites because of the reasons stated above; different miRNA processing by Dicer 




6.4 Epigenetic manipulations. 
6.4.1 CRISPR-Cas9 Strategy. 
Treatment with small molecule inhibitors presumably resulted in demethylation in the 
whole genome including C19MC. Therefore, in this study, I designed a CRISPR/dCas9 
strategy to induce selective demethylation of the normally hypermethylated C19MC 
promoter in HLF cells. 
 
Targeted editing enables for efficient genomic and epigenomic manipulations. New 
techniques, such as CRISPR interference (CRIPSRi) have valuable applications in 
research (Choudary et al., 2015) and substential potential in the clinic. CRISPRi utilizes 
dCas9 fused to effector domains to influence transcription and provides a complementary 
approach to standard RNAi. The difference between CRISPi and RNAi is that CRISPRi 
regulates gene expression primarily at the transcriptional level, while RNAi methods 
control expression at the mRNA level. It has been shown that CRIPSRi can knock down 
a large proportion of the human genome efficiently which can help to identify genetic 
sequences involved in hereditary diseases such as certain forms of cancer (Qi et al., 
2013). In addition, the significance of increased gene expression in a disease can be 
studied by CRIPSRi through the attachment of transcription activators (Larson et al., 
2013). Although this technique is promising in genome editing, it has some limitations 
associated with it. For instance, it can result in unexpected side effects by affecting nearby 
genes. Furthermore, the number of genes that can be targeted is limited due to the fact 
that CRIPSRi, like CRISPR/Cas9, relies on the use of PAM (Larson et al., 2013). 
Nevertheless, the major advantage of this technique is that it can result in efficient and 
significant manipulation in gene expression. Additionally, it is potentially easy to modify 
CRIPSRi, thus it can be used in ex-vivo cell therapy and sequence-targeted medicines 
(Qi et al., 2013). 
 
I initially proposed to employ two different dCas9 constructs, one fused with the catalytic 
domain of DNMT3 to specifically methylate the C19MC promoter in JHH2 and JHH4 HCC 
cell lines that are aberrantly unmethylated and express some C19MC-associated 
miRNAs. However, upon resuscitation from liquid nitrogen, these cell lines failed to 
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proliferate at a rate suitable for transfection (i.e. they were hard to manipulate). Thus, for 
the purpose of this study, I focused on demethylating the C19MC promoter in HLF cells 
using a dCas9-TET fusion (Fig.30) as these cells divide at a much faster rate. 
 
Figure 30 dCas9-Tet strategy. CRIPSR uses a cas9 nuclease, CRIPSR RNA (crRNA) and 
transcript-activating RNA. Fusion of these two RNAs generates the guide RNA which can be 
modified for selective targeting. In this strategy, the target must follow a 5’ NGG PAM sequence. 
PAM motif is critical as it allows binding of guide RNA to the target. Fusion of the dCas9 with the 
catayltic domain of TET enzyme with the guide RNA enables targeted demethylation which occurs 
around gRNA-PAM.  
 
6.4.2 dCas9-TET experiments. 
The dCas9-TET-CD constructs were already established in the Monk laboratory and 
previous experiments using in vitro transcribed mRNA injected into mice embryo 
efficiently resulted in targeted demethylation. This confirms that the dCas9-TET-CD 
construct works when efficiently introduced into cells with gRNAs. Furthermore, several 
studies published since 2016 have used the dCas9-TET fusion system, reporting targeted 
demethylation with an associated induction of transcription and increased mRNA 
abundance of target genes (Liu et al., 2016; Xu et al., 2016). One study in particular used 
transient and lentiviral-based dCas9-Tet systems with four sgRNAs to selectively target 
the BRCA1 promoter to induce gene expression which resulted in a 20% decrease in 
methylation at 3 CpGs and a significant increase in expression (highest upregulation of 




I carefully designed multiple crRNAs to non-repetitive sequences in the C19MC promoter 
to ensure on-target recruitment of the construct. Furthermore, the C19MC CpG island 
contains a tandem repeat of approximately 50 bp to which I also designed a crRNA since 
it had multiple PAM sequences. It is possible that by targeting this interval with a single 
crRNA that the dCas9-TET would be recruited multiple times to each repeat unit. This 
approach of targeting repeat elements has been used to epigenetically manipulate LINE-
1 sequences throughout the mouse genome and was also successfully when using a 
single TET-CD TALEN (Jachowicz et al., 2017). My initial dCas9-TET-CD construct 
delivery with lipofectamine resulted in 10-20% GFP positive cells which unfortunately did 
not survive for FACs selection. We hypothesized that the size of the dCas9-TET-CD 
plasmid (>14kb) might be the limiting factor as the control pMax-GFP plasmid resulted in 
50% higher efficiency. Following transfection of a T2A-puro version of the plamsid using 
PEI, our cells failed to survive selection and no colonies resulted. Ultimately, our attempts 
to efficiently deliver the construct with lipofectamine, PEI and JetPRIME failed and we 
could not obtain sufficient positive integrated cells. 
 
When the laboratories re-opened after the COVID-19 lockdown, I tried to generate stable 
expressing dCas9-TET-CD HepG2 and HLF cells using lentiviral transfer. Recombinant 
lentiviruses have previously been used to infect HCC cells, including HepG2, to enhance 
gene expression (e.g. for CYP3A4) suggesting that our cells lines are accepting of such 
methodology and therefore hold great potential for this work (Chiang et al., 2014). The 
construct generated by the Monk lab is based on the pLV hUbC-dCas9 backbone that 
contain 5’LTR sequences flanking the transgene. However, the sequences contained 
within the 5’LTR sequences, is very large, over 12 kb, which is beyond the recommend 
packaging capacity for most lentiviruses. In parallel, I also tried the Fuw-dCas9-TET- 
CD lentivirus from the Jaenisch laboratory from the Whitehead Institute/MIT as this has a 
smaller transgene because it lacks the T2A-GFP/T2A-puro downstream of dCas9-TET-
CD.  Unfortunately, HepG2 cells failed to proliferate and survive, thus we utilized lentiviral 
transfection into HLF cells only. Following infection, we expanded the cell cultures for 
screening through PCR with dCas9 primers. After confirming that our cell population was 
positive for dCas9, we continued culture to expand only cells with the integrated construct. 
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To produce monoclonal HLF cells with dCas9-TET-CD, I subjected the bulk cultures to 
FACs in order to isolate single cells to grow colonies (performed with the Earlham 
Institute). I obtained several colonies that were all shown to be dCas9 positive by PCR. 
However, being PCR positive does not give information about the plasmid integration site 
or copy number, as a single molecule could have entered a region of heterochromatin 
and be transcriptionally silent. To ensure the monoclonal HLF lines express functional 
dCas9-TET levels, western blotting would need to be performed before transfecting gRNA 
and quantifying the underlying DNA methylation. Unfortunately my time in the lab ended 
before I could finish these experiments and they will be completed by other lab members. 
 
 
6.5 miR-512-3p over-expression. 
Frequent upregulation of C19MC in HCC has been reported indicating the high correlation 
between co-upregulated C19MC expression and tumorigenesis (Augello et al., 2012; 
Nguyen et al., 2017), promoting the invasion and metastasis. Toffanin et al. (2011) and 
Fornari et al. (2012) showed the oncogenic and pro-invasive roles of four C19MC 
members, miR-517a, miR-520c, miR-519d and miR-519c-3p. Upregulation of miR-512-
3p, the first miRNA on the C19MC cluster, was shown to be associated not only with 
tumor burden, stage and grade but also with the poor survival of HCC (Rui et al., 2020). 
Rui and collogues (2020) subsequently used miRNA mimics to overexpress miR-512-3p 
and showed that upregulation of this miRNA inhibited the direct target genes, MAP3K2 
and MAP2K4.   
 
In this study, we also used miRNA mimics to overexpress miR-512-3p. We initially 
proposed to assess the impacts of miRNA upregulation on the target genes. Using miRNA 
target prediction database (miRDB) we checked the targets of miR-512-3p and selected 
8 targets based on their score, oncogenic properties and expression in liver. The targets 
selected were CCDC6, SFMTB1, LATS1, DYRK2, FOXR2, PPARA, JMJDIC and KAT6A, 
however due to having limited time we could not study the impacts of miR-512-3p 




6.6 Impacts of miRNA over-expression on cellular behavior. 
In this study, I performed scratch assays to study cell invasion upon miR-512-3p over-
expression through mimics. Similarly, Rui et al. (2020) performed trans-well assay and in 
vivo studies to assess cell invasion and HCC metastasis in the xenograft models (in nude 
mice) respectively. Their trans-well assay results validated that over-expression of mirR-
512-3p significantly promoted the invasiveness in the HCC cell lines when compared with 
the control.  Additionally, miR-512-3p transfected mice had significantly larger tumor 
volume and weight when compared to the control group. Overall, findings of this study 
suggested that upregulation of miR-512-3p promoted HCC malignancy and early 
recurrence (Rui et al., 2020). Although we did not study cell invasion in vivo, our results 
also suggested that over-expression of miR-512-3p significantly promoted cell invasion 
in HLF cells when compared to the control cells and miRNA control mimic cells. The 
findings of both studies indicated that miR-512-3p can promote HCC, hence suggesting 
that this C19MC miRNA could be a marker for not only detection of HCC but also for 
prediction of therapy targets and outcomes.  
 
6.7 Using miRNA Epigenetics for cancer treatments. 
Despite the improvements in the approaches to prevent (Siegel et al., 2018), detect 
(Chang et al., 2016), diagnose (Liu et al., 2016) and treat (Marrero et al., 2018) HCC 
remains as one of the major factors of tumor-related fatalities. Although the use of 
targeted agents as a part of pharmacological treatment has notably increased the overall 
survival (Llovet et al., 2008; Serper et al., 2017; Kudo et al., 2018), HCC-related deaths 
continue to rise (Yang et al.,2019). It is therefore essential to further study the underlying 
mechanisms of HCC and explore therapeutic targets (Rui et al., 2020). In clinic, use of 
hypermethylation as a prognostic marker could help to predict the effectiveness and 
efficiency of treatments. Moreover, it could be helpful for predicting the disease outcome 
(Mouthino and Esteller, 2017).  
 
The C19MC hypomethylation we observed in this study is HCC specific. C19MC miRNA 
biomarkers can be used to detect HCC and predict worsening of the disease. C19MC 
miRNAs were studied as biomarkers in several cancers. It was reported (Strub et al., 
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2016) that detection of C19MC miRNAs in the circulation of infants with infantile 
hemangioma (IH; the most common vascular tumor of infancy) is promising for IH 
diagnosis in a noninvasive means. miR-519a/d is highly expressed in IH and over-
expression of miR-519a targets RBL2, activating DNMT3B as well as forming embryonal 
tumors (Kleinman et al., 2014). Targets of these miRNAs, including inhibitors of cell 
proliferation and angiogenesis, suggested that C19MC is important in IH pathogenesis 
(Wu et al., 2010; Fornari et al., 2012; Kameswaran et al., 2012; Haecker et al., 2012; 
Vlaschos et al., 2015). Therefore, C19MC miRNA detection may be helpful for identifying 
patients for appropriate therapy as well as monitoring treatment response (Strub et al., 
2016). In addition, to early detection of cancer, detection of circulating C19MC miRNAs; 
miR-516b, miR-517-5p, miR-520a-5p, miR-525-5p and miR-526a has been suggested to 
be associated with preeclampsia (pregnancy related complication) (Hromadnikova et al., 
2013), and the presence of high plasma levels of miR-517-5p might be a predictive of 
preeclampsia (Hromadnikova et al., 2017). Therefore, screening HCC patient plasma for 
free or exosome-derived C19MC miRNAs maybe useful for early disease detection. 
 
Finally, our results showed that upregulation of miR-512-3p significantly promotes cell 
invasion, revelaing the oncogenic properties of this miRNA. Therefore, miR-512-3p could 
serve as a marker to detect and predict the worsening of HCC. In addition to HCC, miR-
512-3p could be studied in other cancer types, such as colorectal and breast cancer, in 
which C19MC-derived miRNAs were reported to be reactivated (Kleinman et al., 2014; 
Ma et al., 2016). Association between miR-512-3p upregulation and cell invasion could 
be translated in other relevant studies in order to validate potential roles of miR-512-3p 
as a diagnostic biomarker in various cancer types. However, using miRNAs as diagnostic 
markers can be challenging due to poor diagnostic specificity and reproducibility of some 
miRNAs. It is crucial to optimize the methods used for miRNA detection prior to use for 
diagnostic purposes to generate useful data (Wang et al., 2016). It is also challenging to 
discover specific miRNAs that can be used as biomarkers in a wide range of patients as 
well as to develop accurate, simple and cheap methods that involve pre- and post-




7. Future Work. 
I quantified five C19MC-derived miRNAs in a panel of HCC cell lines, showing that there 
is a direct relationship between their expression and the promoter methylation status. We 
showed that global methylation could be induced by small molecule inhibitors (5-aza-DC 
and TSA) and that C19MC hypomethylation was sufficient to reactivate miRNAs. We 
could not perform all of the experiments we proposed to do due to COVID-19 lockdown 




7.1 dCas9-TET Experiments – TET Expression. 
We aimed to induce selective demethylation in the C19MC promoter through recruiting a 
dCas9-Tet fusion using multiple guide RNAs. Despite several attempts with different 
transfection reagents, we failed to deliver our construct into our cells. COVID-19 lockdown 
interrupted my study when I was about to use the lentiviral transfection. I did not have 
enough time to validate Tet activity in our stable lines. TET enzymes have been shown 
to have crucial roles in active DNA demethylation through oxidizing 5mC to 5hmC (Gong 
and Zhu, 2011; Nettersheim et al., 2013). Therefore, examining TET expression could 
validate that our cell lines stably express the construct and give more evidence for 
demethylation. Western blotting and immunostaining techniques could be used to test the 
nuclear-localisation of the dCas9-Tet fusion protein. In addition, Epigenase 5mc-
Hydroxylase TET Activity/Inhibition Assay Kit (Colorimetric) could be used to measure 
Tet hydroxylase activity by detecting Tet-converted hydroxymethylated products (BioCat 
GmbH). 
 
If we observed targeted demethylation of the C19MC promoter in HLF cells and the 
concomitant reactivation of the associated miRNAs, it would be benefical to study their 
exprssion using RNA-FISH. Our collaborators (Jérôme Cavaillé at CNRS Toulouse) have 
optimized an imaging technique specific for monitoring C19MC Alu-miRNA expression. 
They use FISH with fluorescent oligonucleotides (Augello et al., 2012), which could be 
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useful to not only to validate the qPCR miRNA results but also to determine the interaction 
with the miRNA processor complex.  
 
7.2 dCas9-DNMT experiments 
As mentioned above, we could not utilize dCas9-DNMT3 in our study as the 
hypomethylated cell lines JHH2 and JHH4 cells did not grow sufficiently. However, 
several studies have shown that dCas9-DNMT fusions can target DNA methylation to 
specific locations of the genome and hence reduced gene expression. For instance, Votja 
and colleagues (2016) utilized a direct fusion of dCas9 to the catalytic domain of DNMT3A 
(dCas9-DNMT3A-CD) to increase the CpG methylation by 60% at the BACH2 loci in 
human HEK293T cells (human embryonic kidney cells) (Votja et al., 2016). While this is 
an impressive increase in methylation, one possible reason for the lack of complete 
hypermethylation is that DNMT3A generally requires a tetramer formation for efficient 
DNA methylation (Huang et al., 2017). To increase the percentage of methylation further, 
chimeric methyltransferase (MTase) fusion proteins were produced. Stepper et al. (2017) 
showed that DNMT3A-DNMT3L chimeric fusion protein induced higher levels of 
methylation than dCas9-DNMT3A-CD alone. Furthermore, a chimeric fusion of three 
dCas9 fused to DNMT3A, DNMT3L and Krupple-associated box (KRAB) protein 
respectively, were shown to result in a greater improvement in methylation efficacy 
(Amabile et al., 2016). This approach would not only target DNA methylation via the action 
of the MTase, but also H3K9 methylation, an epigenetic mark associated with 
hypermethylation due to the recruitment of the co-repressor complex by KRAB-domain. 
In fact, very recent work in the Monk lab has shown that dCas9-ZFP57[KRAB] constructs 
can maintain DNA methylation during embryonic reprogramming, suggesting that KRAB 
recruitment of the co-repressor complex also involved endogenous DNMT3 (personal 
communication Ana Monteagudo-Sánchez). In another study, dCas9-DNMT3A fusion 
protein were used to target the promoters of human CDKN2A and ARF and mouse 
CDKN1a (McDonald et al., 2016). The results of this study demonstrated that the dCas9-
DNMT3A induced methylation and reducing the expression of all three gene, but 
importantly, only when multiple gRNAs were used. For this reason, I have designed 




Overall, many dCas9-based techniques have resulted in a successful (epi)genomic 
editing in vitro in cell lines derived from numerous tissue types, including muscle, liver, 
and kidney. However, it remains limited to cell lines that are easily accept constructs and 
that replicate well in culture. Urbano et al. (2019) proposed that controlling gene 
regulation with epigenetic manipulations will become an increasingly remarkable tool with 
potential for therapeutic use. 
 
7.3 Impacts of miRNA upregulation on target genes. 
As mentioned before, miR-512-3p had the highest increase in fold thus we overexpressed 
miR-512-3p using a mimic. Firstly, miRNA target prediction database (mirDB) was used 
to determine the targets of this miRNA. Rank and score were checked for each of the 
targets. I undertook extensive literature research to determine the oncogenic targets and 
checked the expression of the candidate targets in normal liver and in HCC on human 
tissue atlas. Based on our findings, I selected CCDC6, SFMTB1, LATS1, DYRK2, 
FOXR2, PPARA, JMJDIC and KAT6A genes. Despite optimizing the qRT-PCR conditions 
for these transcripts I did not have sufficient time to look at their expression profile 
following miRNA over-expression. Futhermore, it would be ideal to identify differentially 
expressed genes in an unbiased manner to find novel miR-512-3p targets by RNA-seq 
and correlate the results with the presence of the miRNA binding motif. A direct regulation 
of the target mRNAs could be confirmed by using 3’UTR luciferase assays. 
 
8. Conclusion. 
In the present study, I investigated and quantified several C19MC-derived miRNAs in a 
panel of HCC cell lines (and possible primary cancer tissues) and showed that their 
expression is directly related to the promoter methylation status. Next, we showed that 
hypomethylation induced by 5-aza-DC and TSA resulted in reactivation of miRNAs. Last 
but not least, overexpressing miR-512-3p with mimics promoted cell invasion which 
suggested that this miRNA, with further experimental data, has the potential to be used 
as a predictive marker for HCC and well as a function target to limit HCC invasion. 
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To conclude, as mentioned above, abnormal miRNA expression has been linked with 
pathogenesis, growth and metastasis of tumors and can be used as a novel diagnostic 
or predictive biomarkers in HCC (Augello et al., 2012; Borel et al., 2012; Vaira et al., 
2015). Therefore, studying changes in miRNA expression could help not only to improve 
diagnosis and prognosis but also provide molecular targets for new therapeutic strategies 
against HCC (Augello et al., 2018).  
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